

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A study protocol for a quasi-experimental claims-based study evaluating ten-year results of the population-based integrated health care model 'Gesundes Kinzigtal' (Healthy Kinzigtal): the INTEGRAL study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025945
Article Type:	Protocol
Date Submitted by the Author:	09-Aug-2018
Complete List of Authors:	<p>Schubert, Ingrid; University of Cologne, PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics</p> <p>Siegel, Achim; University Hospital Tübingen, Institute of Occupational and Social Medicine and Health Services Research</p> <p>Graf, Erika; Institute of Medical Biometry and Statistics, Medical Faculty and Medical Center - University of Freiburg</p> <p>Farin, Erik; Institute of Medical Biometry and Statistics, Section of Health Care Research and Rehabilitation Research, Faculty of Medicine and Medical Center – University of Freiburg</p> <p>Ihle, Peter; University of Cologne, PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics</p> <p>Köster , Ingrid ; University of Cologne, PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics</p> <p>Stelzer, Dominikus; Institute of Medical Biometry and Statistics, Section of Health Care Research and Rehabilitation Research, Faculty of Medicine and Medical Center – University of Freiburg</p> <p>Mehl, Claudia; University of Marburg, Institute for Health Services Research and Clinical Epidemiology</p> <p>Schmitz, Jutta; University of Marburg, Institute for Health Services Research and Clinical Epidemiology</p> <p>Dröge, Patrik; Research Institute of the Local Health Care Funds (WIdO), Health Services and Quality Research</p> <p>Guenster, Christian; Research Institute of the Local Health Care Funds (WIdO), Health Services and Quality Research</p> <p>Klöss, Andreas; Research Institute of the Local Health Care Funds (WIdO), Health Services and Quality Research</p> <p>Vach, Werner; University Hospital Basel, Department of Orthopaedics and Traumatology; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg</p> <p>Geraedts, Max; University of Marburg, Institute for Health Services Research and Clinical Epidemiology</p>
Keywords:	Integrated health care, evaluation, indicators, claims data, regional variation

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

Title

A study protocol for a quasi-experimental claims-based study evaluating ten-year results of the population-based integrated health care model 'Gesundes Kinzigtal' (Healthy Kinzigtal): the INTEGRAL study

Schubert I¹, Siegel A², Graf E³, Farin-Glattacker E⁴, Ihle P¹, Köster I¹, Stelzer D³, Mehl C⁵, Schmitz J⁵, Dröge P⁶, Günster C⁶, Klöss A⁶, Vach W^{3,7}, Geraedts M⁵

IS and AS contributed equally as first authors

WV and MG contributed equally as last authors

Correspondence to:

Dr. Erika Graf

Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center -
University of Freiburg, Stefan-Meier-Str. 26, 79104 Freiburg

Phone: +49/761/203-5000

Mail: egr@imbi.uni-freiburg.de

Key words: Integrated health care, evaluation, indicators, claims data, regional variation

Word count: 4.635

ABSTRACT

Introduction: Patients often experience interface problems when treated by different specialists and in different health care sectors. Integrated care concepts aim to reduce these problems. While most integrated health care models focus on individual diseases, the integrated care model 'Gesundes Kinzigtal' applies a population-based approach and addresses the full spectrum of morbidities for a population defined by area of residence – the Kinzigtal. A special feature of the model is the joint savings contract between the regional management company and the statutory health insurers. The INTEGRAL-study aims at assessing the effectiveness of 'Gesundes Kinzigtal' under routine conditions in comparison to conventional care over a period of 10 years in order to understand the benefits but also the potential for (unintended) harms.

Methods and analysis. Database: Claims data from statutory health insurance funds 2005-2015. The evaluation consists of a quasi-experimental study, with Kinzigtal as intervention region, at least 10 further regions with a similar population and health care infrastructure as primary controls, and an additional random sample of insurees from the federal state of Baden-Wuerttemberg as secondary controls. Quality of care will be assessed using indicators developed independently of the evaluation. In addition to specific indicators, 'non-specific' indicators will be used to generate indications of unintended consequences of the model by analysing health care utilisation in general. Temporal trends per indicator in the intervention region will be compared to those in each control region. The overall variation in trends for the indicators across all regions provides information about the potential to modify an indicator due to local differences in the health care system.

Ethics and dissemination. Ethical approval: Ethic Commission of the Faculty of Medicine, Philipps-University Marburg (ek_mr_geraedts_131117). Results will be discussed in workshops, submitted for publication in peer-review journals, and presented at conferences.

Trial Registration number: German Clinical Trials Register (DRKS-00012804).

ARTICLE SUMMARY

A study protocol for a quasi-experimental claims-based study evaluating ten-year results of the population-based integrated health care model 'Gesundes Kinzigtal' (Healthy Kinzigtal): the INTEGRAL study

Strengths and limitations of this study

- Strengths of the present evaluation study include its long observation period and comparisons of the intervention region with regions similar in population and health care infrastructure, which allows to estimate regional variation as well as the effect of the integrated care model.
- The indicators relevant for this assessment will be developed in a structured process independent of the evaluation.
- Another positive feature is the use of 'non-specific indicators' to reveal unintended consequences of the integrated care model and joint savings contract.
- Limitations are those usually associated with collecting claims data, namely, the occurrence of diseases can only be documented and validated internally using the routine data-collecting tools available; patient-reported outcomes (i.e. regarding lifestyle, quality of life, the perception of patient-centered care), data on medical examinations and lab findings are not accessible.
- Moreover, only those services covered by statutory health insurance providers were documented, so that (few) services paid for by the patients themselves were not considered.

INTRODUCTION

Healthcare provision in Germany today is mainly divided into outpatient care (general practitioners (GP) and specialists), hospital care and rehabilitative care. These so-called 'sectoral silos' can be problematic due to their lack of exchange between stakeholders and even lead to poor health outcomes. 'Integrated care' has the potential to address these deficits using new structural approaches beyond the current way of service provision. Close cooperation between GPs, specialists, hospitals and other healthcare stakeholders is intended to lead to more patient-oriented care and cross-sectoral communication. Integrated care aims to improve the quality and cost-effectiveness of healthcare compared to today's situation.¹

The integrated care model 'Gesundes Kinzigtal' (ICM-GK) is considered a best practice example in Germany² and internationally^{3 4} not least due to its population-oriented approach. Compared to other existing models based on the same contractual approach (so-called selective contracting¹) which focus on integrated care for *selected* diseases, ICM-GK addresses the full spectrum of morbidities and health issues for a population defined by residential area (with the only exception of dental care). The contract was concluded in early 2006 between two partners: the Gesundes Kinzigtal GmbH management company (a joint company founded by the 'Medizinisches Qualitätsnetz Ärzteinitiative Kinzigtal e.V.' (MQNK), a regional physicians' network, and OptiMedis AG, a management and holding company specialized in integrated care) and the AOK Baden-Wuerttemberg (the largest statutory health insurance fund in the federal state of Baden-Wuerttemberg). It is a population-based integrated care contract according to § 140 – SGB V (Book V of the German Social Security Code) as of 01 November 2005. Several months after conclusion, the LKK health insurance ('Landwirtschaftliche Krankenkasse') joined the contract. The contract covers the Kinzigtal region, which is located in the Black Forest in southwest Germany and home of about 70,000 people, about 33,000 of whom are insured with the two statutory health insurers that are contract partners. The insurees, doctors and other providers can choose whether they want to join the contract. Even those insurees who decide to enrol into ICM-GK retain the option to visit doctors and other providers who are not part of the contract. Within ICM-GK, patients are entitled to individual targeted, integrated care which focusses on prevention and quality of life for people with chronic diseases. There are no direct financial incentives for insurees to join the contract. A key goal of the integrated care model is the participation (on different levels) and activation of patients: A patient advisory board consisting of several members elected from (and by) the insurees is part of many decision-making processes of the

¹ In general terms a contract between one mandatory health insurance and a single or a group of providers, as opposed to a "collective contract" between all mandatory health insurances and provider umbrella organisations (usually covering a whole region).

1
2
3 'Gesundes Kinzigtal' management.⁵ The patient advisory board elects a patient ombudsman
4 who represents patient interests and mediates in case of conflicts.⁶⁻⁸ ICM-GK aims to
5 improve quality and efficiency in health care by dedicated investments in new activities which
6 improve public health or patient care in the long run but simultaneously reduce costs. This is
7 achieved by means of two strategies:
8
9

- 10 1) Employing both target group-specific and general prevention and healthcare
11 programmes to reduce incidence and prevalence of morbidities or to delay disease
12 progression.
13
- 14 2) Managing inter-sectoral interfaces (in particular between outpatient and inpatient
15 care) in order to improve patient management
16
17

18 The contract between the management company and the statutory health insurers includes a
19 so-called joint savings contract, i.e. the healthcare cost savings achieved are distributed
20 between the contractual partners^{2 6}. Savings are calculated as the difference between the
21 actual healthcare costs and the funds provided to the statutory health insurers to ensure
22 service coverage, which in turn is based on the morbidities prevailing in the region
23 ("morbidity-oriented risk structure compensation scheme"). The calculation of the savings is
24 based on all insurees of both statutory health insurers located in the Kinzigtal, not only those
25 who have enrolled into ICM-GK. Inter alia, this serves to avoid a selection bias in favour of
26 insurees of greater health⁹. Since a joint savings contract can potentially incentivise lower
27 levels of care, i.e. an under-utilisation of health services¹⁰⁻¹², an evaluation of the healthcare
28 quality of the model is of high relevance⁵.
29
30
31
32
33
34

35 The model was built up in several steps between 2006 and 2010. An initial milestone of
36 8,000 insurees of AOK Baden-Wuerttemberg joining was reached in 2011. The start-up
37 phase was accompanied by an evaluation comprising several modules¹³⁻¹⁸. Another external
38 evaluation study of the model also had its primary focus on the start-up phase¹⁷. Generating
39 knowledge about the effectiveness of an integrated care project under routine conditions (i.e.
40 after the completion of the start-up phase in which the commitment of the stakeholders is
41 extraordinary) is of high relevance for all population-based integrated care programmes and
42 physicians' networks in order to understand the true benefits, but also the potential for
43 (unintentional) harm.
44
45
46
47
48
49
50

51 **Research aims:**

52

53 This study protocol describes the evaluation of both the start-up and consolidation phase of
54 the 'Gesundes Kinzigtal' model, with special focus on the latter: In order to assess
55 differences to conventional routine care, the integrated care model should be analysed in its
56
57
58
59
60

1
2
3 routine practice after the completion of the start-up phase, which is now possible for the first
4 time.
5

6 The evaluation uses claims data from the statutory health insurer AOK Baden-Wuerttemberg
7 covering the period 2005 to 2015. The evaluation aims to answer the following questions:
8

- 9
- 10 a) Which indicators can be calculated from claims data in Germany in order to measure
11 differences in patients' treatments and outcomes between intervention group and
12 control groups, with regard to ICM-GK prevention and treatment programmes (ICM-
13 GK programme-specific indicators) as well as health care utilisation and health care
14 of the populations under study in general (ICM-GK programme-unrelated non-specific
15 indicators).
16
 - 17 b) Has the quality of healthcare provided on the basis of the joint savings contract
18 remained stable or improved compared to its baseline level in 2005?
19
 - 20 c) How does the development of healthcare quality during the start-up phase (2006-
21 2010) compare to the development during the consolidation phase (2011-2015)?
22
 - 23 d) Does ICM-GK succeed in avoiding under-utilisation of health services although ICM-
24 GK's revenues are based on a joint savings contract?
25
26

27
28 We expect that the comprehensive set of study indicators based on claims data can also be
29 used for healthcare monitoring in other integrated care models.
30
31

32 33 **METHODS AND DESIGN**

34 35 **Study design:**

36
37 The evaluation consists of a quasi-experimental study, with the Kinzigtal region as the
38 intervention region and at least 10 other regions with a similar population and health care
39 infrastructure as primary controls and an additional random sample of insurees from the
40 federal state of Baden-Wuerttemberg as secondary controls. Figure 1 depicts the study
41 concept.
42
43
44

45
46 Fig 1: Study concept for the evaluation of the integrated care model 'Gesundes Kinzigtal'
47 (ICM-GK)
48
49
50

51
52 - Please insert figure 1 here
53
54
55
56
57
58
59
60

1
2
3 *IC: integrated care*
4
5
6

7 **Work package A: indicator development:**
8

9 A set of quality indicators will be developed to assess the development of quality of care
10 within the study region, and between the study region and the control regions, during the
11 observation period. Based on a mixed methods approach, focus group interviews with
12 stakeholders are combined with a systematic literature review and consensus decision-
13 making.
14
15

16
17 We will develop ICM-GK programme-specific quality indicators to assess ICM-GK goal
18 attainment, and ICM-GK programme-unrelated, non-specific quality indicators to capture
19 potentially unintended consequences of the integrated care model. The indicator
20 development uses, among others, Kessner's tracer concept¹⁹, the OECD-HCQI criteria²⁰ to
21 assess the performance of the health system, and as amended by Fung et al. (2008)²¹,
22 criteria for public reporting initiatives: Thus, above all, indicators should capture
23 effectiveness, safety, patient orientation, and unintended consequences of health care
24 interventions.
25
26
27
28

29
30 Analysing all ICM-GK programs executed during the observation period will be the starting
31 point for the development process. We will then conduct focus group interviews (cf. below,
32 Module A1) and a systematic review of published specific and non-specific indicators
33 (Module A2-A3). Finally, we will decide on the set of indicators for evaluation through
34 consensus decision-making (Module A4).
35
36

37
38 Module A1: focus group interviews: In order to shed light on stakeholders' views on ideal
39 concepts of integrated care and potentially unintended consequences, we will perform semi-
40 structured guided interviews. Six stakeholder groups with 4-6 participants each will be
41 interviewed, consisting of patients from the study region (1) / non-study region patients (2),
42 health care providers from the study region who are (3) / are not (4) members of the ICM-GK
43 provider network / non-study region providers (5), and programme managers and
44 participating sickness funds (6). The interviews will be recorded and transcribed. Potential
45 indicators will be extracted.
46
47
48
49

50
51 Module A2: Development of ICM-GK programme-specific indicators: First, we will analyse
52 programme goals and recommended treatment processes of all ICM-GK programmes
53 carried out during the observation period. Second, appropriate indicators to evaluate these
54 programmes will be developed using a) clinical practice guidelines focusing on the diseases
55 addressed by the ICM-GK programmes; b) quality indicator databases (e.g. National Quality
56
57
58
59

1
2
3 Measures Clearinghouse²², The Ambulatory Care Quality Alliance²³, RAND²⁴, National
4 Quality Forum Quality and Outcomes Framework²⁵, District Health Board New Zealand²⁶,
5 OECD Healthcare Quality Indicators²⁷, and the German databases AQUIK²⁸, QUINTH²⁹, and
6 QISA³⁰); c) a review of articles published in PubMed, Cochrane Library, Embase, Web of
7 Science containing the search terms 'quality indicator*' and 'integrated care'; d) programme-
8 specific indicators mentioned in the focus group interviews. We will describe the indicators
9 according to the scheme developed by the Joint Commission on Accreditation of Healthcare
10 Organizations (1990).³¹

11
12
13
14
15 Module A3: Development of ICM-GK programme-unrelated non-specific indicators: Indicators
16 for the assessment of health care utilisation and the health status of the regional intervention
17 and control populations will serve to identify potential under- or overuse of services that are
18 not in the focus of ICM-GK programmes in the Kinzigtal region. Therefore, we will use OECD
19 indicators (<https://data.oecd.org/health.htm>), the frequency of ICD groups, prescription drug
20 categories (ATC groups), and outpatient or inpatient procedures conducted in the
21 intervention and control regions. We will differentiate between age groups, gender and
22 people with/without multimorbidity.
23
24
25
26

27
28 Module A4: Consensus decision-making: A panel of 10 participants will be invited to finally
29 assess the validity and feasibility of the indicators. As participants we will choose two
30 healthcare providers of the ICM-GK network, two patient representatives of ICM-GK, one
31 sickness fund representative, three members of the evaluation team who were not involved
32 in indicator development and two quality indicator experts. We will use a modified
33 RAND/UCLA Appropriateness Method (RAM)²⁸ and provide participants with information on
34 the indicator development methodology and the consensus process at a first meeting.
35 Participants will receive an online or print version of the indicator set to rate the validity and
36 feasibility of the indicators on a 9-point Likert scale. In a subsequent face-to-face meeting,
37 the participants will be invited to discuss the summary ratings of indicators and comments
38 upon which participants did not agree. Participants will then rate the remaining indicators a
39 second time. Appropriate indicators without disagreement will constitute the final indicator
40 set.
41
42
43
44
45
46

47
48 The indicators pre-specified in work package A will be later supplemented by a data-driven
49 statistical search considering a wide range of non-prespecified indicators based on
50 diagnoses, prescriptions and procedures.
51
52
53
54
55
56
57
58
59
60

Work package B: Claims data analysis of indicators for evaluation:

Database and observation period:

The evaluation is based on retrospective claims data of the major health insurer involved, the AOK Baden-Wuerttemberg. Anonymised data will be provided by the AOK Research Institute (Wissenschaftliches Institut der AOK - WIdO). In addition to master data (with information e.g. concerning age, gender, insurance status and period of insurance), information on the use of all sectors of health care (outpatient care, hospital care, drug prescriptions, benefits in kind, long-term care) is available and can be linked using a non-identifiable study number. For the analysis, ICD-10 coded diagnoses from out- and inpatient care are provided, further medical services according to the EBM Code (physician fee schedule), drug prescription with pharmaceutical registration number and linkage to Anatomical Therapeutic Chemical (ATC) classification and Defined Daily Dose (DDD), hospital stays with e.g. ICD-10 coded diagnoses, procedures ('OPS' Codes) and length of stay, benefits in kinds, information concerning inability to work (diagnosis, duration) and utilisation of long-term care.

Data are provided for the years 2005 to 2015 with 2005 as reference year, i.e. the year before the start of the integrated care programme. 2006 to 2010 form the start-up phase, 2011 to 2015 the consolidation phase.

Target population and control populations:

The target population consists of all AOK insurees living in the intervention region – this results from the conception of the ICM-GK as a regional population-based health care system covering virtually all health care sectors and health conditions. AOK insurees are assigned to the intervention population („Kinzigal population“) if the postal code of their place of residence encodes a place within the Kinzigal region (German postal codes 77709-77797 and 78132). The target population consists of about 30.000 AOK insurees in 2005 and of nearly 32.000 insurees in 2015, and they will be surveyed completely.

Control populations (from regions characterised by 'conventional' or 'usual care') are necessary to check whether the developments observed in the intervention region are actually specific for the latter and may thus be attributed to ICM-GK activities or whether they correspond to a general trend or a small-scale variation pattern which may also occur under other circumstances. For this purpose, we will analyse two types of control populations: First we will consider all AOK insurees from at least 10 control regions (identified by distinct postal codes); these regions shall be structurally similar to the Kinzigal region. A structurally similar control region should meet the following requirements: It should be a geographically contiguous area i) containing only rural communities, small towns or – at most – small medium-sized towns with less than 50.000 inhabitants each; ii) it should preferably be

1
2
3 characterised by a river valley, comparable to the Kinzigtal region; iii) important socio-
4 economic and health service indicators of a control region should not deviate too much from
5 its counterpart in the Kinzigtal region. As important socio-economic and health service
6 indicators we will consider 1) unemployment rate in 2005-2007, 2) income tax per inhabitant
7 in 2005-2007, 3) commuter flow in 2014, 4) proportion of foreign residents in 2015, 5)
8 proportion of employees with academic education in 2015, 6) proportion of employees
9 without training qualifications in 2015, 7) average distance to the closest hospital (in minutes
10 by car), 8) number of inhabitants per office-based general practitioner in 2015, and 9)
11 number of inhabitants per office-based physician or psychotherapist in 2015. Additionally, we
12 will check whether there is an active network of physicians in a given region – a network
13 comparable to the one which was active in the intervention region at the time when the
14 integrated health care system was launched. (We assume that such a network might
15 contribute to an above-average quality of health care.) Our goal is to select 50% of control
16 regions with such a network and 50% without. Apart from this control population, we will draw
17 a random sample of about 500,000 AOK insurees residing in the German federal state of
18 Baden-Wuerttemberg, but outside of the Kinzigtal region. The comparison with the first type
19 of control groups will be our primary comparison, the one with the random sample a
20 secondary comparison.

21
22 Before operationalising and analysing the study populations, we will investigate how many
23 AOK insurees have not been insured continuously throughout a given year or whether
24 insurees were not resident in the region concerned all year round. Depending on this
25 investigation's results, we will settle the final criteria for the inclusion in the study population.

26
27 Health services for AOK insurees in the federal state of Baden-Wuerttemberg outside of the
28 Kinzigtal region are currently largely characterized by family doctor-centred health care – an
29 AOK programme which also aims at a higher quality of health care and requires insurees to
30 enroll, thereby choosing their family doctor. Unfortunately, for some health services this
31 implies a lack of data regarding these patients, as they are covered by a general fee for the
32 GP. Therefore, we have to exclude these patients from the analysis of some indicators.

33 34 35 Operationalization of indicators for data analysis

36
37 In a first step, we operationalise the indicators consented in work package A for the routine
38 data analysis. For indicators expressed as a percentage of a target population, the
39 nominator and denominator have to be defined with the information available in claims data.
40 For each target population, the inclusion and exclusion criteria have to be determined (e.g.
41 ICD-10 codes, validation criteria, insurance period). Indicators will address processes of care
42 as well as outcomes. For the process-related indicators, e.g. billing codes for outpatient care
43 services (EBM codes) and inpatient services (OPS codes) will be used for assessment.

1
2
3 Outcomes are mostly clinical events which can be mapped with diagnoses. Other outcomes
4 refer to the utilisation of special services such as long-term care, palliative care or
5 rehabilitation. All-cause mortality will be assessed using variable 'death' as the reason for
6 leaving the sickness fund.
7

8
9 Statistical considerations:

10 In the descriptive part of the study, we present the percentage of the insured persons or the
11 specific target population fulfilling the respective indicator. For the inferential part, our basic
12 approach is to determine for each indicator and each region the temporal trend in the
13 indicator and to compare the trend observed in the intervention region 'Kinzigtal' with the
14 trends in the control regions. The overall variation in trends across all regions provides
15 information about the potential to modify an indicator due to local differences in the health
16 care system. If there is some variation and if the trend in the intervention region is smaller (or
17 larger) than in all or in the vast majority of control regions, we will regard this as an indication
18 of a specific situation in the intervention region, which is likely to be causally related to the
19 ICM-GK.
20
21
22
23
24
25
26

27 The estimation of the temporal trends will be based on combining regression models for the
28 individual patient data with a standardisation for the population of Baden-Wuerttemberg
29 based on the full random sample from the latter. The choice of the regression models will
30 depend on the type of indicator: For binary indicators, we use logistic regression models, for
31 other types, we select the model accordingly.
32
33

34 In our analytic approach, the following issues will be taken into account:
35

- 36 • *Changes in population over time:* The populations in the regions will change over time
37 due to migration, fertility and mortality. We aim at including at each time point all patients
38 living in the respective region in order to avoid any selection effects. The fact that the
39 same patients will contribute to the same indicator at different time points will be taken
40 into account when assessing statistical significance.
41
- 42 • *Baseline differences across regions:* We avoid any assumptions about similarity across
43 regions at baseline by using regions as fixed effects in all analyses. In spite of the
44 structural similarity of all regions we have to expect differences in the distribution of age,
45 gender, comorbidity, and social status. Consequently, we will adjust all analyses for the
46 first three factors at the individual level and for the fourth factor at the postal code level.
47
- 48 • *Global time trends and structural changes:* Due to using several control regions as well
49 as a sample from the whole BW population, we are able to detect global time trends as
50 well as global structural changes over time, e.g. due to administrative changes in the
51 health care system. We can account for this by using the calendar year as a categorical
52
53
54
55
56
57

1
2
3 covariate in all analyses, and hence require the linearity of region specific trends only in
4 addition to a potentially non-linear global trend.

- 5
6 • *Time window for trends and stability of trends:* For each indicator, we will a priori define a
7 starting point at which we expect a specific change in the time trend (e.g. due to the start
8 of a specific programme) as well as the period over which we expect the change to
9 continue. If the starting point lies within the first 3 years of our observation period, we will
10 also analyse the stability of the trend over time, in particular whether we can find
11 evidence for an attenuation of the trend.
- 12
13 • *Assessing a specific role of the intervention region:* In order to assess a potential specific
14 role of the intervention region, we will visualize trend estimates of all regions in a forest
15 plot as well as in a dot plot. A formal assessment will be based on assessing the
16 statistical significance of a deviation of the intervention region from the mean of all control
17 regions and from the Baden-Wuerttemberg region and on the representation of the
18 deviation of the intervention region from the mean of the control regions as a z-score, i.e.
19 in the unit of the standard deviation of the variation across the control regions.
- 20
21 • *Floor and ceiling effects:* Some regions may for some indicators be already close to the
22 maximum or minimum we can expect. Such circumstances can distort the interpretation
23 of trends. We will take this into account by performing additional analyses which will give
24 more weight to the control regions which are initially similar to the intervention region.
- 25
26 • *Provider effects:* Indicators reflecting an action by a health care provider may be prone to
27 provider effects, i.e. the main source of variation may be differences between providers.
28 We will take this into account when assessing statistical significance whenever the action
29 can be assigned to a health care provider (typically the GP) in our data. In addition,
30 provider variation within regions and their temporal trends will be described and the
31 intervention region will be compared with the control regions.
- 32
33 • *Reducing trends to a single number:* Such a reduction is necessary in order to allow the
34 necessary comparisons between regions. However, this may fail to take a more complex
35 development into account. We will address this issue by always additionally visualizing
36 the raw data behind each estimated trend.
- 37
38 • *Multiplicity:* By comparing the trend estimate in the intervention region simultaneously
39 with all trends in the control regions, we avoid multiple testing when analysing a single
40 indicator. It remains to be borne in mind that we analyse a large number of indicators for
41 a possible specific role of the intervention region. We approach this by assessing global
42 measures such as the number of indicators hinting towards such a specific role or the
43 average difference from the control regions. We will do this in a hierarchical manner,
44 taking into account pre-specified groupings of the indicators, reflecting the suspicion that
45 some indicators might reflect the same signal.
- 46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- *Ranking of non-pre-specified indicators:* A huge number of non-pre-specified indicators will be investigated with the aim to identify the most relevant potential signals. Here we will make use of statistical methods, which have been successfully applied in analysing signals for unknown side-effects of drugs based on routine data.³²

Details of the analytical approach will be fixed in a statistical analysis plan to be finalized prior to starting the analyses.

Data will be stored on MS-SQL Server 2014 under Windows Server 2012. The analysis will be performed with SQL, SAS for Windows Release 9.3 (SAS Institute Inc. Cary, N.C. USA) and Stata 15.1. (StataCorp. 2017. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). The use of claims data follows the Guideline for Good Practice of secondary data analysis³³. Essential parts are contracts with data owner and the regulations for data privacy.

ETHICS AND DISSEMINATION

Ethical approval has been obtained from the Ethic Commission of the Faculty of Medicine, Philipps University Marburg (ek_mr_geraedts_131117). All participants in the focus groups (work package A, cf. figure 1) will give their informed consent, which can be withdrawn at any time during the study. The analysis of the meetings and the presentation of the results (work package C; cf. figure 1) will be is anonymous. Participants will not be identified in any publication.

Access to the claims data is regulated by a contract between the AOK Research Institute (WIdO) and the researchers who analyse the data. Claims data for the evaluation analysis are provided in an anonymised manner, therefore no informed consent is necessary. The internal project study number does not allow any re-identification of the insurees.

After completion of the project, a workshop with relevant stakeholders and participants of the focus groups is planned in order to discuss the results (work package C, cf. figure 1) and to start a process for disseminating results and transferring the methodology used to evaluate an integrated care model. A study report with an executive summary will be produced and will be made available for those contributing to the study and other interested parties.

Besides, results of the study will be presented at scientific conferences and submitted for publication in peer-reviewed journals. The indicators and transfer to routine data analysis will be provided (e.g. via an electronic platform) for those interested in the evaluation of the service quality of population-based integrated care.

DISCUSSION

1
2
3 A solid and thorough assessment of integrated care models is essential to evidence-based
4 health care. A particular feature of this project is the long observation period, which is made
5 possible by using routine data from the statutory health insurance funds. Although
6 investigating the effects of complex interventions by relying on routine data entails certain
7 limitations, it remains a reasonable and acceptable procedure. For example, the Pay-for-
8 Performance (P4P) programme^{34 35}, Preferred Provider Organisation Settings³⁶, and Patient-
9 centered Medical Home^{37 38} were assessed with administrative data. In Germany, data from
10 health insurance funds were used to evaluate disease management programmes (DMP)^{39 40}
11 and family doctor-centered care (Hausarztzentrierte Versorgung)⁴¹⁻⁴³ as well as models of
12 integrated care^{44 45}, not least because of their advantages such as availability for long
13 periods of time without additional data collection, no selection, interviewer or recall bias –
14 thus reflecting everyday practice of health care.
15
16
17
18
19

20 Our study aims to show whether the ICM-GK's standard of care is at least equivalent, better
21 or worse than that of 'conventional' or 'usual care' during the consolidation phase of ICM-GK.
22 This project reveals evidence for the design of the population-based integrated care contract
23 not only for the ICM-GK, but also for health insurers and other stakeholders of health care
24 structures in Germany. Should this evaluation reveal weaknesses in certain areas (such as
25 under-use or inadequate care), similarly-structured types of care involving selective contracts
26 could make it possible to take countermeasures (i.e. committing to continuous and prompt
27 monitoring of care by employing specific codes or the obligatory publication of results as well
28 as the redrafting of certain contractual regulations such as joint savings contracts).
29
30
31
32

33 The indicators developed here can also be employed to control quality and managed health
34 care in other types of integrated care, and for monitoring the provision of standard care. The
35 development process of the indicators, involving relevant stakeholders, ensures their
36 relevance for the practice and for health care provision itself.
37
38
39
40
41

42 **Author affiliations**

43
44 ¹PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy
45 and Psychosomatic, University of Cologne, Herderstraße 52, 50931 Cologne, Germany
46

47 ²Institute of Occupational and Social Medicine and Health Services Research – University
48 Hospital Tübingen; Wilhelmstr. 27, 72074 Tübingen, Germany
49

50
51 ³ Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center -
52 University of Freiburg, Stefan-Meier-Str. 26, 79104 Freiburg, Germany
53
54
55
56
57
58
59
60

⁴Institute of Medical Biometry and Statistics, Section of Health Care Research and Rehabilitation Research, Faculty of Medicine and Medical Center - University of Freiburg, Hugstetter Str. 49, 79106 Freiburg, Germany

⁵Institute for Health Services Research and Clinical Epidemiology, University Marburg; Karl-von-Frisch-Straße 4, 35043 Marburg, Germany

⁶ AOK Research Institute (WIdO), Berlin; Rosenthaler Straße 31, 10178 Berlin, Germany

⁷ Department of Orthopaedics and Traumatology, University Hospital Basel, Spitalstr. 21, 4031 Basel, Switzerland

Ethical approval: The study has been granted ethical approval by Ethic Commission of the Faculty of Medicine, Philipps-University Marburg (ek_mr_geraedts_131117).

AUTHOR CONTRIBUTIONS

MG, EFG, EG, IS, AS and WV are principle investigators and responsible for the study design and project management. CG, PD, AK, IK and PI are responsible for data provision, data collection, and data management. IK, PI, DS, WV and EG are responsible for the statistical analysis, AS and WV for the concept of defining control regions. MG, JS and CM are responsible for the indicator development, IK and IS for the operationalisation of indicators with routine data. All authors reviewed and approved the final version of the study protocol.

Provenance and peer review. Externally peer reviewed

Funding statement

The project is funded by the Innovation Committee of the Joint Federal Committee after peer review by the scientific advisory board under the grant number 01VSF16002.

Competing interests: AS declares involvement in former studies on Gesundes Kinzigtal GmbH (2006-2015) and an employment at Gesundes Kinzigtal GmbH (01-June-2015 until 31-December-2015). IS, IK and PI declare that they were involved in one former study evaluating the start-up phase (2006-2011) of the integrated care model 'Gesundes Kinzigtal'. The other authors declare no competing interests.

Patient consent: not required

Acknowledgements: The authors would like to thank the AOK Baden-Wuerttemberg for data access and Susanne Sollmann (WIdO) for her help with translating the protocol. The article processing charge was funded by the German Research Foundation (DFG) and the University of Freiburg in the funding programme Open Access Publishing.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data statement: Technical appendix, details on statistics, and data tabulations will be made available from <http://www.pmvforschungsgruppe.de>.


For peer review only

REFERENCES

1. Groene O, Pimperl A, Hildebrandt H. The Role of Integrated Care and Population Health. Cham Palgrave Macmillan, 2017.
2. Sachverständigenrat zur Begutachtung der Entwicklung im Gesundheitswesen. Koordination und Integration. Gesundheitsversorgung in einer Gesellschaft des längeren Lebens. Sondergutachten 2009. Langfassung, 2009.
3. Pimperl A, Hildebrandt H, Gröne O, et al. Case Study: Gesundes Kinzigtal Germany. In: McClellan M, ed. *Accountable Care in Practice: Global Perspectives*. Durham: Duke-Margolis Center for Health Policy, 2017.
4. Groene O, Pfaff H, Hildebrandt H. Germany: Scaling Up a Population-Based Integrated Healthcare System: The Case of "Healthy Kinzigtal" in Germany. In: Jeffrey Braithwaite RM, Yukihiro Matsuyama, Paul Shekelle, Stuart Whittaker and Samir Al-Adawi, ed. *Health Systems Improvement Across the Globe: Success Stories from 60 Countries*. Boca Raton, London, New York: CRC Press 2018.
5. Siegel A, Stossel U, Schubert I, et al. [Problems of evaluating regional integrated care using the example of "Gesundes Kinzigtal Integrated Care"]. *Z Evid Fortbild Qual Gesundheitswes* 2011;105(8):590-96.
6. Herrmann C, Hildebrandt H, Richter-Reichhelm M, et al. Das Modell „Gesundes Kinzigtal“ – Managementgesellschaft organisiert Integrierte Versorgung einer definierten Population auf Basis eines Einsparcontractings. *Gesundheits Sozialpolitik* 2006;5(6):11-29.
7. Hildebrandt H, Herrmann C, Knittel R, et al. Gesundes Kinzigtal Integrated Care: improving population health by a shared health gain approach and a shared savings contract. *International Journal of Integrated Care* 2010;10
8. Pimperl A, Schreyögg J, Rothgang H, et al. Ökonomische Erfolgsmessung von integrierten Versorgungsnetzen – Gütekriterien, Herausforderungen, Best-Practice-Modell. *Das Gesundheitswesen* 2015;77(12):e184-e93.
9. Siegel A, Köster I, Schubert I, et al. Utilization dynamics of an integrated care system in Germany: Morbidity, age, and sex distribution of Gesundes Kinzigtal integrated care's membership in 2006–2008. In: Janssen C, Swart E, Lengerke T, eds. *Health care utilization in Germany Theory, Methodology, and Results* Foreword by Ronald M Anderson. New York: Springer 2014:321-35.
10. Porter ME, Teisberg EO. *Redefining health care: creating value-based competition on results*: Harvard Business Press 2006.
11. Berchtold P, Hess K. Evidenz für managed care: europäische Literaturanalyse unter besonderer Berücksichtigung der Schweiz: Wirkung von Versorgungssteuerung auf Qualität und Kosteneffektivität. Neuchatel: Schweizerisches Gesundheitsobservatorium 2006.
12. Jacobs K, Schulze S. Managed Care und integrierte Versorgung in den USA – Erfahrungen und Lehren für die Diskussion in Deutschland. In: Klauber J, Robra BP, Schellschmidt H, eds. *Krankenhaus-Report: Wege zur Integration*. Stuttgart: Schattauer-Verlag 2005:81-97.
13. Hölzel L, Vollmer M, Kriston L, et al. Patientenbeteiligung bei medizinischen Entscheidungen in der Integrierten Versorgung Gesundes Kinzigtal: Ergebnisse einer kontrollierten Kohortenstudie. *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 2012;55(11-12):1524-33.
14. Mnich E, Hofreuter-Gätgens K, Salomon T, et al. Ergebnis-Evaluation einer Gesundheitsförderungsmaßnahme für ältere Menschen. *Gesundheitswesen* 2013;75(02):e5-e10. doi: 10.1055/s-0032-1311617 [published Online First: 21.05.2012]
15. Siegel A, Stöbel U. Prozessevaluation aus Sicht der Leistungserbringer: Ergebnisse der Erst-, Zweit- und Drittbefragung der Leistungspartner (PeGL-Projekt), Teil III. EKIV Newsletter Freiburg: Evaluations-Koordinierungsstelle Integrierte Versorgung Gesundes Kinzigtal, 2012:4-7.

16. Hildebrandt H, Pimperl A, Schulte T, et al. Triple Aim – Evaluation in der Integrierten Versorgung Gesundes Kinzigtal – Gesundheitszustand, Versorgungserleben und Wirtschaftlichkeit. *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 2015;58(4-5):383-92.
17. Schubert I, Siegel A, Köster I, et al. Evaluation der populationsbezogenen ,Integrierten Versorgung Gesundes Kinzigtal (IVGK). Ergebnisse zur Versorgungsqualität auf der Basis von Routinedaten. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2016;117:27-37.
18. Siegel A, Stöbel U. Patientenorientierung und Partizipative Entscheidungsfindung in der Integrierten Versorgung Gesundes Kinzigtal. In: Pundt J, ed. *Patientenorientierung: Wunsch oder Wirklichkeit*. Bremen: Apollon 2014:195-230.
19. Kessner DM, Kalk CE, Singer J. Assessing Health Quality-the Case for Tracers. *New England Journal of Medicine* 1973;288(4):189-94. doi: 10.1056/nejm197301252880406
20. Arah OA, Westert GP, Hurst J, et al. A conceptual framework for the OECD Health Care Quality Indicators Project. *International Journal for Quality in Health Care* 2006;18(suppl_1):5-13. doi: 10.1093/intqhc/mzl024
21. Fung CH, Lim Y-W, Mattke S, et al. Systematic review: the evidence that publishing patient care performance data improves quality of care. *Annals of internal medicine* 2008;148(2):111-23.
22. AHRQ. National Quality Clearinghouse [Available from: <https://www.qualitymeasures.ahrq.gov/> accessed 10.07 2018.
23. AHRQ. The Ambulatory Care Quality Alliance: Improving Clinical Quality and Consumer Decisionmaking [Available from: <https://archive.ahrq.gov/professionals/quality-patient-safety/quality-resources/tools/ambulatory-care/background.html> accessed 10.07. 2018.
24. RAND Corporation. Health Care Quality Indicators 2018 [Available from: <https://www.rand.org/topics/health-care-quality-indicators.html> accessed 10.07. 2018.
25. National Health Service. Quality and Outcomes Framework 2018 [Available from: <https://www.nhs.uk/prescription-data/prescribing-data/quality-and-outcomes-framework-qof> accessed 10.07.2018.
26. District Health Board New Zealand. 2018 [Available from: <https://www.health.govt.nz/new-zealand-health-system/key-health-sector-organisations-and-people/district-health-boards> accessed 10.07.2018.
27. OECD Healthcare Quality Indicators. 2018 [Available from: <http://www.oecd.org/els/health-systems/health-care-quality-indicators.htm> accessed 10.07.2018.
28. Kleudgen S, Diel F, Burgdorf F, et al. KBV entwickelt Starter-Set ambulanter Qualitätsindikatoren– AQUIK®-Set. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2011;105(1):54-63.
29. QUINTH. Qualitätsindikatorethesaurus: GKV Spitzenverband; 2018 [Available from: <https://quinth.gkv-spitzenverband.de/content/index.php> accessed 10.07. 2018.
30. QiSA. Das Indikatorensystem für die ambulante Versorgung: AOK Gesundheitskasse; 2018 [Available from: <http://www.aok-gesundheitspartner.de/bund/qisa/index.html> accessed 10.07. 2018.
31. Joint Commission on Accreditation of Healthcare Organizations (JCAHO). Primer on indicator development and application: measuring quality in health care. Oakbrook Terrace, Ill: JCAHO 1990.
32. Efron B. Size, Power and False Discovery Rates. *The Annals of Statistics* 2007;35(4):1351-77.
33. Swart E, Ihle P, Gothe H. Gute Praxis Sekundärdatenanalyse (GPS). Die 2. Revision. *Das Gesundheitswesen* 2012;74(08/09):A123.
34. Levin-Scherz J, DeVita N, Timbie J. Impact of pay-for-performance contracts and network registry on diabetes and asthma HEDIS® measures in an integrated delivery network. *Medical Care Research and Review* 2006;63(1_suppl):14S-28S.
35. Fagan PJ, Schuster AB, Boyd C, et al. Chronic Care Improvement in Primary Care: Evaluation of an Integrated Pay-for-Performance and Practice-Based Care Coordination Program among Elderly Patients with Diabetes. *Health Services Research* 2010;45(6p1):1763-82.

- 1
2
3 36. Gilmore AS, Zhao Y, Kang N, et al. Patient outcomes and evidence-based medicine in a preferred
4 provider organization setting: a six-year evaluation of a physician pay-for-performance
5 program. *Health Services Research* 2007;42(6p1):2140-59.
- 6 37. DeVries A, Li C, Sridhar G, et al. Impact of medical homes on quality, healthcare utilization, and
7 costs. *The American Journal of Managed Care* 2012;18(9):534-44.
- 8 38. Rosenthal MB, Friedberg MW, Singer SJ, et al. Effect of a multipayer patient-centered medical
9 home on health care utilization and quality: the Rhode Island chronic care sustainability
10 initiative pilot program. *JAMA Internal Medicine* 2013;173(20):1907-13.
- 11 39. Miksch A, Laux G, Ose D, et al. Is there a survival benefit within a German primary care-based
12 disease management program? *The American journal of managed care* 2010;16(1):49-54.
- 13 40. Linder R, Ahrens S, Köppel D, et al. Nutzen und Effizienz des Disease-Management-Programms
14 Diabetes mellitus Typ 2. *Deutsches Ärzteblatt* 2011;108(10):155-62.
- 15 41. Roehl I, Beyer M, Gondan M, et al. Leitliniengerechte Behandlung bei chronischer Herzinsuffizienz
16 im Rahmen der Hausarztzentrierten Versorgung. Ergebnisse einer Evaluationsstudie.
17 *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2013;107(6):394-402.
- 18 42. Laux G, Szecsenyi J, Mergenthal K, et al. Hausarztzentrierte Versorgung in Baden-Württemberg.
19 *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 2015;58(4-5):398-407.
- 20 43. Gerlach F, Szecsenyi J. Evaluation der Hausarztzentrierten Versorgung (HzV) nach § 73b SGB V in
21 Baden-Württemberg (2013–2016). *Ergebnisbericht (Stand 0909 2014) Frankfurt und*
22 *Heidelberg Verfügbar unter www.aok-bw-presse.de/src/php/download.php* 2014
- 23 44. Braun G, Gröbner M, Seitz R. Evaluation vernetzter Versorgungsstrukturen: Ergebnisse einer
24 empirischen Untersuchung. *Gesundheitsökonomie & Qualitätsmanagement*
25 2008;13(06):358-64.
- 26 45. Kerkemeyer L, Mostardt S, Biermann J, et al. Evaluation of an integrated care program for
27 schizophrenia: concept and study design. *European archives of psychiatry and clinical*
28 *neuroscience* 2015;265(2):155-62. doi: 10.1007/s00406-014-0508-6 [published Online First:
29 2014/06/08]
- 30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



BMJ Open

A study protocol for a quasi-experimental claims-based study evaluating ten-year results of the population-based integrated health care model 'Gesundes Kinzigtal' (Healthy Kinzigtal): the INTEGRAL study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025945.R1
Article Type:	Protocol
Date Submitted by the Author:	01-Oct-2018
Complete List of Authors:	<p>Schubert, Ingrid; University of Cologne, PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics</p> <p>Siegel, Achim; University Hospital Tübingen, Institute of Occupational and Social Medicine and Health Services Research</p> <p>Graf, Erika; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg</p> <p>Farin, Erik; Institute of Medical Biometry and Statistics, Section of Health Care Research and Rehabilitation Research, Faculty of Medicine and Medical Center – University of Freiburg</p> <p>Ihle, Peter; University of Cologne, PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics</p> <p>Köster , Ingrid ; University of Cologne, PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics</p> <p>Stelzer, Dominikus; Institute of Medical Biometry and Statistics, Section of Health Care Research and Rehabilitation Research, Faculty of Medicine and Medical Center – University of Freiburg</p> <p>Mehl, Claudia; University of Marburg, Institute for Health Services Research and Clinical Epidemiology</p> <p>Schmitz, Jutta; University of Marburg, Institute for Health Services Research and Clinical Epidemiology</p> <p>Dröge, Patrik; Research Institute of the Local Health Care Funds (WIdO), Health Services and Quality Research</p> <p>Guenster, Christian; Research Institute of the Local Health Care Funds (WIdO), Health Services and Quality Research</p> <p>Klöss, Andreas; Research Institute of the Local Health Care Funds (WIdO), Health Services and Quality Research</p> <p>Vach, Werner; University Hospital Basel, Department of Orthopaedics and Traumatology; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg</p> <p>Geraedts, Max; University of Marburg, Institute for Health Services Research and Clinical Epidemiology</p>
Primary Subject Heading:	Health services research

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary Subject Heading:	Public health, Research methods
Keywords:	Integrated health care, evaluation, indicators, claims data, regional variation



Title

A study protocol for a quasi-experimental claims-based study evaluating ten-year results of the population-based integrated health care model 'Gesundes Kinzigtal' (Healthy Kinzigtal): the INTEGRAL study

Schubert I¹, Siegel A², Graf E³, Farin-Glattacker E⁴, Ihle P¹, Köster I¹, Stelzer D³, Mehl C⁵, Schmitz J⁵, Dröge P⁶, Guenster C⁶, Klöss A⁶, Vach W^{3,7}, Geraedts M⁵

IS and AS contributed equally as first authors

WV and MG contributed equally as last authors

Correspondence to:

Dr. Erika Graf

Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center -
University of Freiburg, Stefan-Meier-Str. 26, 79104 Freiburg

Phone: +49/761/203-5000

Mail: egr@imbi.uni-freiburg.de

Key words: Integrated health care, evaluation, indicators, claims data, regional variation

Word count: 4.877

ABSTRACT

Introduction: Patients often experience interface problems when treated by different specialists and in different health care sectors. Integrated care concepts aim to reduce these problems. While most integrated health care models focus on individual diseases, the integrated care model 'Gesundes Kinzigtal' applies a population-based approach and addresses the full spectrum of morbidities for a population defined by area of residence – the Kinzigtal. A special feature of the model is the joint savings contract between the regional management company and the statutory health insurers. The INTEGRAL-study aims at assessing the effectiveness of 'Gesundes Kinzigtal' under routine conditions in comparison to conventional care over a period of 10 years in order to understand the benefits but also the potential for (unintended) harms.

Methods and analysis. Database: Claims data from statutory health insurance funds 2005-2015. The evaluation consists of a quasi-experimental study, with Kinzigtal as intervention region, at least 10 further regions with a similar population and health care infrastructure as primary controls, and an additional random sample of insurees from the federal state of Baden-Wuerttemberg as secondary controls. Model-specific and 'non-specific' indicators, adopted from the literature and enriched by focus group interviews will be used to evaluate the model's effectiveness and potential unintended consequences by analysing health care utilisation in general. Temporal trends per indicator in the intervention region will be compared to those in each control region. The overall variation in trends for the indicators across all regions provides information about the potential to modify an indicator due to local differences in the health care system.

Ethics and dissemination. Ethical approval: Ethic Commission of the Faculty of Medicine, Philipps-University Marburg (ek_mr_geraedts_131117). Results will be discussed in workshops, submitted for publication in peer-review journals, and presented at conferences.

Trial Registration number: German Clinical Trials Register (DRKS00012804).

ARTICLE SUMMARY

A study protocol for a quasi-experimental claims-based study evaluating ten-year results of the population-based integrated health care model 'Gesundes Kinzigtal' (Healthy Kinzigtal): the INTEGRAL study

Strengths and limitations of this study

- Strengths of the present evaluation study include its long observation period and comparisons of the intervention region with regions similar in population and health care infrastructure, which allows to estimate regional variation as well as the effect of the integrated care model.
- The indicators relevant for this assessment will be developed in a structured process independent of the evaluation.
- Another positive feature is the use of 'non-specific indicators' to reveal unintended consequences of the integrated care model and joint savings contract.
- Limitations are those usually associated with collecting claims data, namely, the occurrence of diseases can only be documented and validated internally using the routine data-collecting tools available; patient-reported outcomes (i.e. regarding lifestyle, quality of life, the perception of patient-centered care), data on medical examinations and lab findings are not accessible.
- Moreover, only those services covered by statutory health insurance providers were documented, so that (few) services paid for by the patients themselves were not considered.

INTRODUCTION

Healthcare provision in Germany today is mainly divided into outpatient care (general practitioners (GP) and specialists), hospital care and rehabilitative care. These so-called 'sectoral silos' can be problematic due to their lack of exchange between stakeholders and even lead to poor health outcomes. 'Integrated care' has the potential to address these deficits using new structural approaches beyond the current way of service provision. Close cooperation between GPs, specialists, hospitals and other healthcare stakeholders is intended to lead to more patient-oriented care and cross-sectoral communication. Integrated care aims to improve the quality and cost-effectiveness of healthcare compared to today's situation.¹

The integrated care model 'Gesundes Kinzigtal' (ICM-GK) is considered a best practice example in Germany² and internationally^{3 4} not least due to its population-oriented approach. Compared to other existing models based on the same contractual approach (so-called selective contracting¹) which focus on integrated care for *selected* diseases, ICM-GK addresses the full spectrum of morbidities and health issues for a population defined by residential area (with the only exception of dental care). The contract was concluded in early 2006 between two partners: the Gesundes Kinzigtal GmbH management company (a joint company founded by the 'Medizinisches Qualitätsnetz Ärzteinitiative Kinzigtal e.V.' (MQNK), a regional physicians' network, and OptiMedis AG, a management and holding company specialized in integrated care) and the AOK Baden-Wuerttemberg (the largest statutory health insurance fund in the federal state of Baden-Wuerttemberg). It is a population-based integrated care contract according to § 140 – SGB V (Book V of the German Social Security Code) as of 01 November 2005. Several months after conclusion, the LKK health insurance ('Landwirtschaftliche Krankenkasse') joined the contract. The contract covers the Kinzigtal region, which is located in the Black Forest in southwest Germany and home of about 70,000 people, about 33,000 of whom are insured with the two statutory health insurers that are contract partners. The insurees, doctors and other providers can choose whether they want to join the contract. Even those insurees who decide to enrol into ICM-GK retain the option to visit doctors and other providers who are not part of the contract. Within ICM-GK, patients are entitled to individual targeted, integrated care which focusses on prevention and quality of life for people with chronic diseases. There are no direct financial incentives for insurees to join the contract. A key goal of the integrated care model is the participation (on different levels) and activation of patients: A patient advisory board consisting of several members elected from (and by) the insurees is part of many decision-making processes of the

¹ In general terms a contract between one mandatory health insurance and a single or a group of providers, as opposed to a "collective contract" between all mandatory health insurances and provider umbrella organisations (usually covering a whole region).

1
2
3 'Gesundes Kinzigtal' management.⁵ The patient advisory board elects a patient ombudsman
4 who represents patient interests and mediates in case of conflicts.⁶⁻⁸ ICM-GK aims to
5 improve quality and efficiency in health care by dedicated investments in new activities which
6 improve public health or patient care in the long run but simultaneously reduce costs. This is
7 achieved by means of two strategies:
8
9

- 10 1) Employing both target group-specific and general prevention and healthcare
11 programmes to reduce incidence and prevalence of morbidities or to delay disease
12 progression.
13
- 14 2) Managing inter-sectoral interfaces (in particular between outpatient and inpatient
15 care) in order to improve patient management
16
17

18 The contract between the management company and the statutory health insurers includes a
19 so-called joint savings contract, i.e. the healthcare cost savings achieved are distributed
20 between the contractual partners^{2 6}. Savings are calculated as the difference between the
21 actual healthcare costs and the funds provided to the statutory health insurers to ensure
22 service coverage, which in turn is based on the morbidities prevailing in the region
23 ("morbidity-oriented risk structure compensation scheme"). The calculation of the savings is
24 based on all insurees of both statutory health insurers located in the Kinzigtal, not only those
25 who have enrolled into ICM-GK. Inter alia, this serves to avoid a selection bias in favour of
26 insurees of greater health⁹. Since a joint savings contract can potentially incentivise lower
27 levels of care, i.e. an under-utilisation of health services¹⁰⁻¹², an evaluation of the healthcare
28 quality of the model is of high relevance⁵.
29
30
31
32
33
34

35 The model was built up in several steps between 2006 and 2010. An initial milestone of
36 8,000 insurees of AOK Baden-Wuerttemberg joining was reached in 2011. The start-up
37 phase was accompanied by an evaluation comprising several modules¹³⁻¹⁸. Another external
38 evaluation study of the model also had its primary focus on the start-up phase¹⁷. Generating
39 knowledge about the effectiveness of an integrated care project under routine conditions (i.e.
40 after the completion of the start-up phase in which the commitment of the stakeholders is
41 extraordinary) is of high relevance for all population-based integrated care programmes and
42 physicians' networks in order to understand the true benefits, but also the potential for
43 (unintentional) harm.
44
45
46
47
48
49
50

51 **Research aims:**

52

53 This study protocol describes the evaluation of both the start-up and consolidation phase of
54 the 'Gesundes Kinzigtal' model, with special focus on the latter: In order to assess
55 differences to conventional routine care, the integrated care model should be analysed in its
56
57
58
59
60

1
2
3 routine practice after the completion of the start-up phase, which is now possible for the first
4 time.
5

6 The evaluation uses claims data from the statutory health insurer AOK Baden-Wuerttemberg
7 covering the period 2005 to 2015. The evaluation aims to answer the following questions:
8

- 9
- 10 a) Which indicators can be calculated from claims data in Germany in order to measure
11 differences in patients' treatments and outcomes between intervention group and
12 control groups, with regard to ICM-GK prevention and treatment programmes (ICM-
13 GK programme-specific indicators) as well as health care utilisation and health care
14 of the populations under study in general (ICM-GK programme-unrelated non-specific
15 indicators).
16
 - 17 b) Has the quality of healthcare provided on the basis of the joint savings contract
18 remained stable or improved compared to its baseline level in 2005?
19
 - 20 c) How does the development of healthcare quality during the start-up phase (2006-
21 2010) compare to the development during the consolidation phase (2011-2015)?
22
 - 23 d) Does ICM-GK succeed in avoiding under-utilisation of health services although ICM-
24 GK's revenues are based on a joint savings contract?
25
26

27
28 We expect that the comprehensive set of study indicators based on claims data can also be
29 used for healthcare monitoring in other integrated care models.
30
31

32 33 **METHODS AND DESIGN**

34 35 **Study design:**

36
37 The evaluation consists of a quasi-experimental study, with the Kinzigtal region as the
38 intervention region and at least 10 other regions with a similar population and health care
39 infrastructure as primary controls and an additional random sample of insurees from the
40 federal state of Baden-Wuerttemberg as secondary controls. Figure 1 depicts the study
41 concept.
42
43
44

45
46 Fig 1: Study concept for the evaluation of the integrated care model 'Gesundes Kinzigtal'
47 (ICM-GK)
48
49
50

51
52 - Please insert figure 1 here
53
54
55
56
57
58
59
60

1
2
3 *IC: integrated care*
4
5
6

7 **Work package A: indicator development:**
8

9 A set of quality indicators will be developed to assess the development of quality of care
10 within the study region, and between the study region and the control regions, during the
11 observation period. Based on a mixed methods approach, focus group interviews with
12 stakeholders are combined with a systematic literature review and consensus decision-
13 making.
14
15

16
17 We will develop ICM-GK programme-specific quality indicators to assess ICM-GK goal
18 attainment, and ICM-GK programme-unrelated, non-specific quality indicators to capture
19 potentially unintended consequences of the integrated care model. The indicator
20 development uses, among others, Kessner's tracer concept¹⁹, the OECD-HCQI criteria²⁰ to
21 assess the performance of the health system, and as amended by Fung et al. (2008)²¹,
22 criteria for public reporting initiatives: Thus, above all, indicators should capture
23 effectiveness, safety, patient orientation, and unintended consequences of health care
24 interventions.
25
26
27
28

29
30 Analysing all ICM-GK programs executed during the observation period will be the starting
31 point for the development process. We will then conduct focus group interviews (cf. below,
32 Module A1) and a systematic review of published specific and non-specific indicators
33 (Module A2-A3). Finally, we will decide on the set of indicators for evaluation through
34 consensus decision-making (Module A4).
35
36

37
38 Module A1: focus group interviews: In order to shed light on stakeholders' views on ideal
39 concepts of integrated care and potentially unintended consequences, we will perform semi-
40 structured guided interviews. Six stakeholder groups with 4-6 participants each will be
41 interviewed, consisting of patients from the study region (1) / non-study region patients (2),
42 health care providers from the study region who are (3) / are not (4) members of the ICM-GK
43 provider network / non-study region providers (5), and programme managers and
44 participating sickness funds (6). The interviews will be recorded and transcribed. Potential
45 indicators will be extracted.
46
47
48
49

50
51 Module A2: Development of ICM-GK programme-specific indicators: First, we will analyse
52 programme goals and recommended treatment processes of all ICM-GK programmes
53 carried out during the observation period. Second, appropriate indicators to evaluate these
54 programmes will be developed using a) clinical practice guidelines focusing on the diseases
55 addressed by the ICM-GK programmes; b) quality indicator databases (e.g. National Quality
56
57
58
59

1
2
3 Measures Clearinghouse²², The Ambulatory Care Quality Alliance²³, RAND²⁴, National
4 Quality Forum Quality and Outcomes Framework²⁵, District Health Board New Zealand²⁶,
5 OECD Healthcare Quality Indicators²⁷, and the German databases AQUIK²⁸, QUINTH²⁹, and
6 QISA³⁰); c) a review of articles published in PubMed, Cochrane Library, Embase, Web of
7 Science containing the search terms 'quality indicator*' and 'integrated care'; d) programme-
8 specific indicators mentioned in the focus group interviews. Two independent reviewers will
9 screen abstracts and full texts of articles, guidelines and QI databases for indicators suitable
10 to measure the quality of programme-specific processes and outcomes of care. We will
11 search the mentioned databases for English and German articles without time limit. Our
12 focus will be on indicators assessing integrated care, health promotion and prevention. We
13 will exclude indicators focusing on practice management and in-hospital care. All potential
14 indicators will be extracted and entered into a database using the scheme developed by the
15 Joint Commission on Accreditation of Healthcare Organizations (1990)³¹ to describe the
16 indicators. We will eliminate duplicates and check whether the respective indicator could be
17 calculated using routine claims data of German sickness funds. The final list of suitable
18 indicators will be assessed by the consensus panel (see A4).

19
20
21
22
23
24
25
26
27 Module A3: Development of ICM-GK programme-unrelated non-specific indicators: Indicators
28 for the assessment of health care utilisation and the health status of the regional intervention
29 and control populations will serve to identify potential under- or overuse of services that are
30 not in the focus of ICM-GK programmes in the Kinzigtal region. Therefore, we will use OECD
31 indicators (<https://data.oecd.org/health.htm>), the frequency of ICD groups, prescription drug
32 categories (ATC groups), and outpatient or inpatient procedures conducted in the
33 intervention and control regions. We will differentiate between age groups, gender and
34 people with/without multimorbidity.

35
36
37
38
39
40 Module A4: Consensus decision-making: A panel of 10 participants will be invited to finally
41 assess the validity and feasibility of the indicators. As participants we will choose two
42 healthcare providers of the ICM-GK network, two patient representatives of ICM-GK, one
43 sickness fund representative, three members of the evaluation team who were not involved
44 in indicator development and two quality indicator experts. We will use a modified
45 RAND/UCLA Appropriateness Method (RAM)²⁸ and provide participants with information on
46 the indicator development methodology and the consensus process at a first meeting.
47 Participants will receive an online or print version of the indicator set to rate the validity and
48 feasibility of the indicators on a 9-point Likert scale. In a subsequent face-to-face meeting,
49 the participants will be invited to discuss the summary ratings of indicators and comments
50 upon which participants did not agree. Participants will then rate the remaining indicators a

1
2
3 second time. Appropriate indicators without disagreement will constitute the final indicator
4 set.
5

6 The indicators pre-specified in work package A will be later supplemented by a data-driven
7 statistical search considering a wide range of non-prespecified indicators based on
8 diagnoses, prescriptions and procedures.
9
10

11 12 13 **Work package B: Claims data analysis of indicators for evaluation:** 14

15 Database and observation period: 16

17 The evaluation is based on retrospective claims data of the major health insurer involved, the
18 AOK Baden-Wuerttemberg. Anonymised data will be provided by the AOK Research Institute
19 (Wissenschaftliches Institut der AOK - WIdO). In addition to master data (with information
20 e.g. concerning age, gender, insurance status and period of insurance), information on the
21 use of all sectors of health care (outpatient care, hospital care, drug prescriptions, benefits in
22 kind, long-term care) is available and can be linked using a non-identifiable study number.
23 For the analysis, ICD-10 coded diagnoses – available since the year 2000 - from out- and
24 inpatient care are provided, further medical services according to the EBM Code (physician
25 fee schedule), drug prescription with pharmaceutical registration number and linkage to
26 Anatomical Therapeutic Chemical (ATC) classification and Defined Daily Dose (DDD),
27 hospital stays with e.g. ICD-10 coded diagnoses, procedures ('OPS' Codes) and length of
28 stay, benefits in kinds, information concerning inability to work (diagnosis, duration) and
29 utilisation of long-term care.
30
31

32 Data are provided for the years 2005 to 2015 with 2005 as reference year, i.e. the year
33 before the start of the integrated care programme. The ICM GK project defined a number of
34 8.000 enrolled patients as a precondition to open the program for other sickness funds. This
35 number was reached in 2011, therefore we will take the years 2006 to 2010 as the start-up
36 phase, 2011 to 2015 as the consolidation phase. Furthermore, the increase of enrollments
37 has remarkably slowed down from 2011, showing that enrolment dynamics is another feature
38 suggesting that we may differentiate those two development phases.
39
40
41
42
43
44
45
46
47
48
49

50 Target population and control populations: 51

52 The target population consists of all AOK insurees living in the intervention region
53 irrespective of any enrollment – this results from the conception of the ICM-GK as a regional
54 population-based health care system covering virtually all health care sectors and health
55
56
57
58
59
60

1
2
3 conditions. AOK insurees are assigned to the intervention population („Kinzigal population“) if the postal code of their place of residence encodes a place within the Kinzigal region (German postal codes 77709-77797 and 78132). The target population consists of about 4
5 30.000 AOK insurees in 2005 and of nearly 32.000 insurees in 2015, and they will be 6
7 surveyed completely. 8
9

10 Control populations (from regions characterised by ‘conventional’ or ‘usual care’) are 11
12 necessary to check whether the developments observed in the intervention region are 13
14 actually specific for the latter and may thus be attributed to ICM-GK activities or whether they 15
16 correspond to a general trend or a small-scale variation pattern which may also occur under 17
18 other circumstances. For this purpose, we will analyse two types of control populations: First 19
20 we will consider all AOK insurees from at least 10 control regions (identified by distinct postal 21
22 codes); these regions shall be structurally similar to the Kinzigal region. A structurally similar 23
24 control region should meet the following requirements: It should be a geographically 25
26 contiguous area i) containing only rural communities, small towns or – at most – small 27
28 medium-sized towns with less than 50.000 inhabitants each; ii) it should preferably be 29
30 characterised by a river valley, comparable to the Kinzigal region; iii) important socio- 31
32 economic and health service indicators of a control region should not deviate too much from 33
34 its counterpart in the Kinzigal region. As important socio-economic and health service 35
36 indicators we will consider 1) unemployment rate in 2005-2007, 2) income tax per inhabitant 37
38 in 2005-2007, 3) commuter flow in 2014, 4) proportion of foreign residents in 2015, 5) 39
40 proportion of employees with academic education in 2015, 6) proportion of employees 41
42 without training qualifications in 2015, 7) average distance to the closest hospital (in minutes 43
44 by car), 8) number of inhabitants per office-based general practitioner in 2015, and 9) 45
46 number of inhabitants per office-based physician or psychotherapist in 2015. Additionally, we 47
48 will check whether there is an active network of physicians in a given region – a network 49
50 comparable to the one which was active in the intervention region at the time when the 51
52 integrated health care system was launched. (We assume that such a network might 53
54 contribute to an above-average quality of health care.) Our goal is to select 50% of control 55
56 regions with such a network and 50% without. Apart from this control population, we will draw 57
58 a random sample of about 500,000 AOK insurees residing in the German federal state of 59
59 Baden-Wuerttemberg, but outside of the Kinzigal region. The comparison with the first type 60
60 of control groups will be our primary comparison, the one with the random sample a 10
61
62 secondary comparison.

63 Before operationalising and analysing the study populations, we will investigate how many 64
65 AOK insurees have not been insured continuously throughout a given year or whether 66
67
68
69
70

1
2
3 insurees were not resident in the region concerned all year round. Depending on this
4 investigation's results, we will settle the final criteria for the inclusion in the study population.
5

6 Health services for AOK insurees in the federal state of Baden-Wuerttemberg outside of the
7 Kinzigtal region are currently largely characterized by family doctor-centred health care – an
8 AOK programme which also aims at a higher quality of health care and requires insurees to
9 enroll, thereby choosing their family doctor. Unfortunately, for some health services this
10 implies a lack of data regarding these patients, as they are covered by a general fee for the
11 GP. Therefore, we have to exclude these patients from the analysis of some indicators.
12
13
14

15 16 Operationalization of indicators for data analysis

17
18 In a first step, we operationalise the indicators consented in work package A for the routine
19 data analysis. For indicators expressed as a percentage of a target population, the
20 nominator and denominator have to be defined with the information available in claims data.
21 For each target population, the inclusion and exclusion criteria have to be determined (e.g.
22 ICD-10 codes, validation criteria, insurance period). Indicators will address processes of care
23 as well as outcomes. For the process-related indicators, e.g. billing codes for outpatient care
24 services (EBM codes) and inpatient services (OPS codes) will be used for assessment.
25 Outcomes are mostly clinical events which can be mapped with diagnoses. Other outcomes
26 refer to the utilisation of special services such as long-term care, palliative care or
27 rehabilitation. All-cause mortality will be assessed using variable 'death' as the reason for
28 leaving the sickness fund.
29
30
31
32
33
34
35
36

37 Statistical considerations:

38 In the descriptive part of the study, we present the percentage of the insured persons or the
39 specific target population fulfilling the respective indicator. For the inferential part, our basic
40 approach is to determine for each indicator and each region the temporal trend in the
41 indicator and to compare the trend observed in the intervention region 'Kinzigtal' with the
42 trends in the control regions. The overall variation in trends across all regions provides
43 information about the potential to modify an indicator due to local differences in the health
44 care system. If there is some variation and if the trend in the intervention region is smaller (or
45 larger) than in all or in the vast majority of control regions, we will regard this as an indication
46 of a specific situation in the intervention region, which is likely to be causally related to the
47 ICM-GK.
48
49
50
51
52
53
54

55 The estimation of the temporal trends will be based on combining regression models for the
56 individual patient data with a standardisation for the population of Baden-Wuerttemberg
57
58
59

1
2
3 based on the full random sample from the latter. The choice of the regression models will
4 depend on the type of indicator: For binary indicators, we use logistic regression models, for
5 other types, we select the model accordingly.
6

7 In our analytic approach, the following issues will be taken into account:

- 8
9 • *Changes in population over time*: The populations in the regions will change over time
10 due to migration, fertility and mortality. We aim at including at each time point all patients
11 living in the respective region in order to avoid any selection effects. The fact that the
12 same patients will contribute to the same indicator at different time points will be taken
13 into account when assessing statistical significance.
14
- 15
16 • *Baseline differences across regions*: We avoid any assumptions about similarity across
17 regions at baseline by using regions as fixed effects in all analyses. In spite of the
18 structural similarity of all regions we have to expect differences in the distribution of age,
19 gender, comorbidity, and social status. Consequently, we will adjust all analyses for the
20 first three factors at the individual level and for the fourth factor at the postal code level.
21
- 22
23 • *Global time trends and structural changes*: Due to using several control regions as well
24 as a sample from the whole BW population, we are able to detect global time trends as
25 well as global structural changes over time, e.g. due to administrative changes in the
26 health care system. We can account for this by using the calendar year as a categorical
27 covariate in all analyses, and hence require the linearity of region specific trends only in
28 addition to a potentially non-linear global trend.
29
- 30
31 • *Time window for trends and stability of trends*: For each indicator, we will a priori define a
32 starting point at which we expect a specific change in the time trend (e.g. due to the start
33 of a specific programme) as well as the period over which we expect the change to
34 continue. If the starting point lies within the first 3 years of our observation period, we will
35 also analyse the stability of the trend over time, in particular whether we can find
36 evidence for an attenuation of the trend.
37
- 38
39 • *Assessing a specific role of the intervention region*: In order to assess a potential specific
40 role of the intervention region, we will visualize trend estimates of all regions in a forest
41 plot as well as in a dot plot. A formal assessment will be based on assessing the
42 statistical significance of a deviation of the intervention region from the mean of all control
43 regions and from the Baden-Wuerttemberg region and on the representation of the
44 deviation of the intervention region from the mean of the control regions as a z-score, i.e.
45 in the unit of the standard deviation of the variation across the control regions.
46
- 47
48 • *Floor and ceiling effects*: Some regions may for some indicators be already close to the
49 maximum or minimum we can expect. Such circumstances can distort the interpretation
50 of trends. We will take this into account by performing additional analyses which will give
51 more weight to the control regions which are initially similar to the intervention region.
52
53
54
55
56
57
58
59
60

- *Provider effects*: Indicators reflecting an action by a health care provider may be prone to provider effects, i.e. the main source of variation may be differences between providers. We will take this into account when assessing statistical significance whenever the action can be assigned to a health care provider (typically the GP) in our data. In addition, provider variation within regions and their temporal trends will be described and the intervention region will be compared with the control regions.
- *Reducing trends to a single number*: Such a reduction is necessary in order to allow the necessary comparisons between regions. However, this may fail to take a more complex development into account. We will address this issue by always additionally visualizing the raw data behind each estimated trend.
- *Multiplicity*: By comparing the trend estimate in the intervention region simultaneously with all trends in the control regions, we avoid multiple testing when analysing a single indicator. It remains to be borne in mind that we analyse a large number of indicators for a possible specific role of the intervention region. We approach this by assessing global measures such as the number of indicators hinting towards such a specific role or the average difference from the control regions. We will do this in a hierarchical manner, taking into account pre-specified groupings of the indicators, reflecting the suspicion that some indicators might reflect the same signal.
- *Ranking of non-pre-specified indicators*: A huge number of non-pre-specified indicators will be investigated with the aim to identify the most relevant potential signals. Here we will make use of statistical methods, which have been successfully applied in analysing signals for unknown side-effects of drugs based on routine data.³²

Details of the analytical approach will be fixed in a statistical analysis plan to be finalized prior to starting the analyses.

Data will be stored on MS-SQL Server 2014 under Windows Server 2012. The analysis will be performed with SQL, SAS for Windows Release 9.3 (SAS Institute Inc. Cary, N.C. USA) and Stata 15.1. (StataCorp. 2017. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). The use of claims data follows the Guideline for Good Practice of secondary data analysis³³. Essential parts are contracts with data owner and the regulations for data privacy.

'PATIENT AND PUBLIC INVOLVEMENT'

Patients and public were not involved in the study design nor will they be involved in the recruitment and conduct of the study. Patient will be involved in focus groups addressing

1
2
3 aspects of integrated care and in the consensus panel assessing validity and feasibility of the
4 indicators for evaluation.
5

6 **ETHICS AND DISSEMINATION**

7
8 Ethical approval has been obtained from the Ethic Commission of the Faculty of Medicine,
9 Philipps University Marburg (ek_mr_geraedts_131117). All participants in the focus groups
10 (work package A, cf. figure 1) will give their informed consent, which can be withdrawn at any
11 time during the study. The analysis of the meetings and the presentation of the results (work
12 package C; cf. figure 1) will be is anonymous. Participants will not be identified in any
13 publication.
14
15
16

17
18 Access to the claims data is regulated by a contract between the AOK Research Institute
19 (WIdO) and the researchers who analyse the data. Claims data for the evaluation analysis
20 are provided in an anonymised manner, therefore no informed consent is necessary. The
21 internal project study number does not allow any re-identification of the insurees.
22
23

24
25 After completion of the project, a workshop with relevant stakeholders and participants of the
26 focus groups is planned in order to discuss the results (work package C, cf. figure 1) and to
27 start a process for disseminating results and transferring the methodology used to evaluate
28 an integrated care model. A study report with an executive summary will be produced and
29 will be made available for those contributing to the study and other interested parties.
30
31

32
33 Besides, results of the study will be presented at scientific conferences and submitted for
34 publication in peer-reviewed journals. The indicators and transfer to routine data analysis will
35 be provided (e.g. via an electronic platform) for those interested in the evaluation of the
36 service quality of population-based integrated care.
37
38

39 **DISCUSSION**

40
41 A solid and thorough assessment of integrated care models is essential to evidence-based
42 health care. A particular feature of this project is the long observation period, which is made
43 possible by using routine data from the statutory health insurance funds. Although
44 investigating the effects of complex interventions by relying on routine data entails certain
45 limitations, it remains a reasonable and acceptable procedure. For example, the Pay-for-
46 Performance (P4P) programme^{34 35}, Preferred Provider Organisation Settings³⁶, and Patient-
47 centered Medical Home^{37 38} were assessed with administrative data. In Germany, data from
48 health insurance funds were used to evaluate disease management programmes (DMP)^{39 40}
49 and family doctor-centered care (Hausarztzentrierte Versorgung)⁴¹⁻⁴³ as well as models of
50 integrated care^{44 45}, not least because of their advantages such as availability for long
51 periods of time without additional data collection, no selection, interviewer or recall bias –
52 thus reflecting everyday practice of health care.
53
54
55
56
57
58
59
60

Our study aims to show whether the ICM-GK's standard of care is at least equivalent, better or worse than that of 'conventional' or 'usual care' during the consolidation phase of ICM-GK. This project reveals evidence for the design of the population-based integrated care contract not only for the ICM-GK, but also for health insurers and other stakeholders of health care structures in Germany. Should this evaluation reveal weaknesses in certain areas (such as under-use or inadequate care), similarly-structured types of care involving selective contracts could make it possible to take countermeasures (i.e. committing to continuous and prompt monitoring of care by employing specific codes or the obligatory publication of results as well as the redrafting of certain contractual regulations such as joint savings contracts).

The indicators developed here can also be employed to control quality and managed health care in other types of integrated care, and for monitoring the provision of standard care. The development process of the indicators, involving relevant stakeholders, ensures their relevance for the practice and for health care provision itself.

Author affiliations

¹PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatic, University of Cologne, Herderstraße 52, 50931 Cologne, Germany

²Institute of Occupational and Social Medicine and Health Services Research – University Hospital Tübingen; Wilhelmstr. 27, 72074 Tübingen, Germany

³ Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Stefan-Meier-Str. 26, 79104 Freiburg, Germany

⁴Institute of Medical Biometry and Statistics, Section of Health Care Research and Rehabilitation Research, Faculty of Medicine and Medical Center - University of Freiburg, Hugstetter Str. 49, 79106 Freiburg, Germany

⁵Institute for Health Services Research and Clinical Epidemiology, University Marburg; Karl-von-Frisch-Straße 4, 35043 Marburg, Germany

⁶ AOK Research Institute (WIdO), Berlin; Rosenthaler Straße 31, 10178 Berlin, Germany

⁷ Department of Orthopaedics and Traumatology, University Hospital Basel, Spitalstr. 21, 4031 Basel, Switzerland

Ethical approval: The study has been granted ethical approval by Ethic Commission of the Faculty of Medicine, Philipps-University Marburg (ek_mr_geraedts_131117).

AUTHOR CONTRIBUTIONS

1
2
3 MG, EFG, EG, IS, AS and WV are principle investigators and responsible for the study
4 design and project management. CG, PD, AK, IK and PI are responsible for data provision,
5 data collection, and data management. IK, PI, DS, WV and EG are responsible for the
6 statistical analysis, AS and WV for the concept of defining control regions. MG, JS and CM
7 are responsible for the indicator development, IK and IS for the operationalisation of
8 indicators with routine data. All authors reviewed and approved the final version of the study
9 protocol.

10
11
12
13 **Provenance and peer review.** Externally peer reviewed

14 **Funding statement**

15
16
17
18 The project is funded by the Innovation Committee of the Joint Federal Committee after peer
19 review by the scientific advisory board under the grant number 01VSF16002.

20
21 **Competing interests:** AS declares involvement in former studies on Gesundes Kinzigtal
22 GmbH (2006-2015) and an employment at Gesundes Kinzigtal GmbH (01-June-2015 until
23 31-December-2015). IS, IK and PI declare that they were involved in one former study
24 evaluating the start-up phase (2006-2011) of the integrated care model 'Gesundes Kinzigtal'.
25 All authors report grants from the Innovation Committee of the Joint Federal Committee,
26 during the conduct of the study.

27
28
29
30 **Patient consent:** not required

31
32
33 **Acknowledgements:** The authors would like to thank the AOK Baden-Wuerttemberg for
34 data access and Susanne Sollmann (WIdO) for her help with translating the protocol. The
35 article processing charge was funded by the German Research Foundation (DFG) and the
36 University of Freiburg in the funding programme Open Access Publishing.

37
38
39
40 **Data statement:** Technical appendix, details on statistics, and data tabulations will be made
41 available from <http://www.pmvforschungsguppe.de>.


REFERENCES

1. Groene O, Pimperl A, Hildebrandt H. The Role of Integrated Care and Population Health. Cham Palgrave Macmillan, 2017.
2. Sachverständigenrat zur Begutachtung der Entwicklung im Gesundheitswesen. Koordination und Integration. Gesundheitsversorgung in einer Gesellschaft des längeren Lebens. Sondergutachten 2009. Langfassung, 2009.
3. Pimperl A, Hildebrandt H, Gröne O, et al. Case Study: Gesundes Kinzigtal Germany. In: McClellan M, ed. *Accountable Care in Practice: Global Perspectives*. Durham: Duke-Margolis Center for Health Policy, 2017.
4. Groene O, Pfaff H, Hildebrandt H. Germany: Scaling Up a Population-Based Integrated Healthcare System: The Case of "Healthy Kinzigtal" in Germany. In: Jeffrey Braithwaite RM, Yukihiro Matsuyama, Paul Shekelle, Stuart Whittaker and Samir Al-Adawi, ed. *Health Systems Improvement Across the Globe: Success Stories from 60 Countries*. Boca Raton, London, New York: CRC Press 2018.
5. Siegel A, Stossel U, Schubert I, et al. [Problems of evaluating regional integrated care using the example of "Gesundes Kinzigtal Integrated Care"]. *Z Evid Fortbild Qual Gesundheitswes* 2011;105(8):590-96.
6. Herrmann C, Hildebrandt H, Richter-Reichhelm M, et al. Das Modell „Gesundes Kinzigtal“ – Managementgesellschaft organisiert Integrierte Versorgung einer definierten Population auf Basis eines Einsparcontractings. *Gesundheits Sozialpolitik* 2006;5(6):11-29.
7. Hildebrandt H, Herrmann C, Knittel R, et al. Gesundes Kinzigtal Integrated Care: improving population health by a shared health gain approach and a shared savings contract. *International Journal of Integrated Care* 2010;10
8. Pimperl A, Schreyögg J, Rothgang H, et al. Ökonomische Erfolgsmessung von integrierten Versorgungsnetzen – Gütekriterien, Herausforderungen, Best-Practice-Modell. *Das Gesundheitswesen* 2015;77(12):e184-e93.
9. Siegel A, Köster I, Schubert I, et al. Utilization dynamics of an integrated care system in Germany: Morbidity, age, and sex distribution of Gesundes Kinzigtal integrated care's membership in 2006–2008. In: Janssen C, Swart E, Lengerke T, eds. *Health care utilization in Germany Theory, Methodology, and Results* Foreword by Ronald M Anderson. New York: Springer 2014:321-35.
10. Porter ME, Teisberg EO. *Redefining health care: creating value-based competition on results*: Harvard Business Press 2006.
11. Berchtold P, Hess K. Evidenz für managed care: europäische Literaturanalyse unter besonderer Berücksichtigung der Schweiz: Wirkung von Versorgungssteuerung auf Qualität und Kosteneffektivität. Neuchatel: Schweizerisches Gesundheitsobservatorium 2006.
12. Jacobs K, Schulze S. Managed Care und integrierte Versorgung in den USA – Erfahrungen und Lehren für die Diskussion in Deutschland. In: Klauber J, Robra BP, Schellschmidt H, eds. *Krankenhaus-Report: Wege zur Integration*. Stuttgart: Schattauer-Verlag 2005:81-97.
13. Hölzel L, Vollmer M, Kriston L, et al. Patientenbeteiligung bei medizinischen Entscheidungen in der Integrierten Versorgung Gesundes Kinzigtal: Ergebnisse einer kontrollierten Kohortenstudie. *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 2012;55(11-12):1524-33.
14. Mnich E, Hofreuter-Gätgens K, Salomon T, et al. Ergebnis-Evaluation einer Gesundheitsförderungsmaßnahme für ältere Menschen. *Gesundheitswesen* 2013;75(02):e5-e10. doi: 10.1055/s-0032-1311617 [published Online First: 21.05.2012]
15. Siegel A, Stößel U. Prozessevaluation aus Sicht der Leistungserbringer: Ergebnisse der Erst-, Zweit- und Drittbefragung der Leistungspartner (PeGL-Projekt), Teil III. EKIV Newsletter Freiburg: Evaluations-Koordinierungsstelle Integrierte Versorgung Gesundes Kinzigtal, 2012:4-7.

16. Hildebrandt H, Pimperl A, Schulte T, et al. Triple Aim – Evaluation in der Integrierten Versorgung Gesundes Kinzigtal – Gesundheitszustand, Versorgungserleben und Wirtschaftlichkeit. *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 2015;58(4-5):383-92.
17. Schubert I, Siegel A, Köster I, et al. Evaluation der populationsbezogenen ,Integrierten Versorgung Gesundes Kinzigtal (IVGK). Ergebnisse zur Versorgungsqualität auf der Basis von Routinedaten. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2016;117:27-37.
18. Siegel A, Stöbel U. Patientenorientierung und Partizipative Entscheidungsfindung in der Integrierten Versorgung Gesundes Kinzigtal. In: Pundt J, ed. *Patientenorientierung: Wunsch oder Wirklichkeit*. Bremen: Apollon 2014:195-230.
19. Kessner DM, Kalk CE, Singer J. Assessing Health Quality-the Case for Tracers. *New England Journal of Medicine* 1973;288(4):189-94. doi: 10.1056/nejm197301252880406
20. Arah OA, Westert GP, Hurst J, et al. A conceptual framework for the OECD Health Care Quality Indicators Project. *International Journal for Quality in Health Care* 2006;18(suppl_1):5-13. doi: 10.1093/intqhc/mzl024
21. Fung CH, Lim Y-W, Mattke S, et al. Systematic review: the evidence that publishing patient care performance data improves quality of care. *Annals of internal medicine* 2008;148(2):111-23.
22. AHRQ. National Quality Clearinghouse [Available from: <https://www.qualitymeasures.ahrq.gov/> accessed 10.07 2018.
23. AHRQ. The Ambulatory Care Quality Alliance: Improving Clinical Quality and Consumer Decisionmaking [Available from: <https://archive.ahrq.gov/professionals/quality-patient-safety/quality-resources/tools/ambulatory-care/background.html> accessed 10.07. 2018.
24. RAND Corporation. Health Care Quality Indicators 2018 [Available from: <https://www.rand.org/topics/health-care-quality-indicators.html> accessed 10.07. 2018.
25. National Health Service. Quality and Outcomes Framework 2018 [Available from: <https://www.nhs.uk/prescription-data/prescribing-data/quality-and-outcomes-framework-qof> accessed 10.07.2018.
26. District Health Board New Zealand. 2018 [Available from: <https://www.health.govt.nz/new-zealand-health-system/key-health-sector-organisations-and-people/district-health-boards> accessed 10.07.2018.
27. OECD Healthcare Quality Indicators. 2018 [Available from: <http://www.oecd.org/els/health-systems/health-care-quality-indicators.htm> accessed 10.07.2018.
28. Kleudgen S, Diel F, Burgdorf F, et al. KBV entwickelt Starter-Set ambulanter Qualitätsindikatoren– AQUIK®-Set. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2011;105(1):54-63.
29. QUINTH. Qualitätsindikatorethesaurus: GKV Spitzenverband; 2018 [Available from: <https://quinth.gkv-spitzenverband.de/content/index.php> accessed 10.07. 2018.
30. QiSA. Das Indikatorensystem für die ambulante Versorgung: AOK Gesundheitskasse; 2018 [Available from: <http://www.aok-gesundheitspartner.de/bund/qisa/index.html> accessed 10.07. 2018.
31. Joint Commission on Accreditation of Healthcare Organizations (JCAHO). Primer on indicator development and application: measuring quality in health care. Oakbrook Terrace, Ill: JCAHO 1990.
32. Efron B. Size, Power and False Discovery Rates. *The Annals of Statistics* 2007;35(4):1351-77.
33. Swart E, Ihle P, Gothe H. Gute Praxis Sekundärdatenanalyse (GPS). Die 2. Revision. *Das Gesundheitswesen* 2012;74(08/09):A123.
34. Levin-Scherz J, DeVita N, Timbie J. Impact of pay-for-performance contracts and network registry on diabetes and asthma HEDIS® measures in an integrated delivery network. *Medical Care Research and Review* 2006;63(1_suppl):14S-28S.
35. Fagan PJ, Schuster AB, Boyd C, et al. Chronic Care Improvement in Primary Care: Evaluation of an Integrated Pay-for-Performance and Practice-Based Care Coordination Program among Elderly Patients with Diabetes. *Health Services Research* 2010;45(6p1):1763-82.

- 1
2
3 36. Gilmore AS, Zhao Y, Kang N, et al. Patient outcomes and evidence-based medicine in a preferred
4 provider organization setting: a six-year evaluation of a physician pay-for-performance
5 program. *Health Services Research* 2007;42(6p1):2140-59.
- 6 37. DeVries A, Li C, Sridhar G, et al. Impact of medical homes on quality, healthcare utilization, and
7 costs. *The American Journal of Managed Care* 2012;18(9):534-44.
- 8 38. Rosenthal MB, Friedberg MW, Singer SJ, et al. Effect of a multipayer patient-centered medical
9 home on health care utilization and quality: the Rhode Island chronic care sustainability
10 initiative pilot program. *JAMA Internal Medicine* 2013;173(20):1907-13.
- 11 39. Miksch A, Laux G, Ose D, et al. Is there a survival benefit within a German primary care-based
12 disease management program? *The American journal of managed care* 2010;16(1):49-54.
- 13 40. Linder R, Ahrens S, Köppel D, et al. Nutzen und Effizienz des Disease-Management-Programms
14 Diabetes mellitus Typ 2. *Deutsches Ärzteblatt* 2011;108(10):155-62.
- 15 41. Roehl I, Beyer M, Gondan M, et al. Leitliniengerechte Behandlung bei chronischer Herzinsuffizienz
16 im Rahmen der Hausarztzentrierten Versorgung. Ergebnisse einer Evaluationsstudie.
17 *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2013;107(6):394-402.
- 18 42. Laux G, Szecsenyi J, Mergenthal K, et al. Hausarztzentrierte Versorgung in Baden-Württemberg.
19 *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 2015;58(4-5):398-407.
- 20 43. Gerlach F, Szecsenyi J. Evaluation der Hausarztzentrierten Versorgung (HzV) nach § 73b SGB V in
21 Baden-Württemberg (2013–2016). *Ergebnisbericht (Stand 0909 2014) Frankfurt und*
22 *Heidelberg Verfügbar unter www.aok-bw-presse.de/src/php/download.php* 2014
- 23 44. Braun G, Gröbner M, Seitz R. Evaluation vernetzter Versorgungsstrukturen: Ergebnisse einer
24 empirischen Untersuchung. *Gesundheitsökonomie & Qualitätsmanagement*
25 2008;13(06):358-64.
- 26 45. Kerkemeyer L, Mostardt S, Biermann J, et al. Evaluation of an integrated care program for
27 schizophrenia: concept and study design. *European archives of psychiatry and clinical*
28 *neuroscience* 2015;265(2):155-62. doi: 10.1007/s00406-014-0508-6 [published Online First:
29 2014/06/08]
- 30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Study concept for the evaluation of the integrated care model 'Gesundes Kinzigtal' (ICM-GK)

179x101mm (300 x 300 DPI)

BMJ Open

A study protocol for a quasi-experimental claims-based study evaluating ten-year results of the population-based integrated health care model 'Gesundes Kinzigtal' (Healthy Kinzigtal): the INTEGRAL study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-025945.R2
Article Type:	Protocol
Date Submitted by the Author:	15-Oct-2018
Complete List of Authors:	<p>Schubert, Ingrid; University of Cologne, PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics</p> <p>Siegel, Achim; University Hospital Tübingen, Institute of Occupational and Social Medicine and Health Services Research</p> <p>Graf, Erika; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg</p> <p>Farin, Erik; Institute of Medical Biometry and Statistics, Section of Health Care Research and Rehabilitation Research, Faculty of Medicine and Medical Center – University of Freiburg</p> <p>Ihle, Peter; University of Cologne, PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics</p> <p>Köster , Ingrid ; University of Cologne, PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics</p> <p>Stelzer, Dominikus; Institute of Medical Biometry and Statistics, Section of Health Care Research and Rehabilitation Research, Faculty of Medicine and Medical Center – University of Freiburg</p> <p>Mehl, Claudia; University of Marburg, Institute for Health Services Research and Clinical Epidemiology</p> <p>Schmitz, Jutta; University of Marburg, Institute for Health Services Research and Clinical Epidemiology</p> <p>Dröge, Patrik; Research Institute of the Local Health Care Funds (WIdO), Health Services and Quality Research</p> <p>Guenster, Christian; Research Institute of the Local Health Care Funds (WIdO), Health Services and Quality Research</p> <p>Klöss, Andreas; Research Institute of the Local Health Care Funds (WIdO), Health Services and Quality Research</p> <p>Vach, Werner; University Hospital Basel, Department of Orthopaedics and Traumatology; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg</p> <p>Geraedts, Max; University of Marburg, Institute for Health Services Research and Clinical Epidemiology</p>
Primary Subject Heading:	Health services research

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary Subject Heading:	Public health, Research methods
Keywords:	Integrated health care, evaluation, indicators, claims data, regional variation



Title

A study protocol for a quasi-experimental claims-based study evaluating ten-year results of the population-based integrated health care model 'Gesundes Kinzigtal' (Healthy Kinzigtal): the INTEGRAL study

Schubert I¹, Siegel A², Graf E³, Farin-Glattacker E⁴, Ihle P¹, Köster I¹, Stelzer D³, Mehl C⁵, Schmitz J⁵, Dröge P⁶, Guenster C⁶, Klöss A⁶, Vach W^{3,7}, Geraedts M⁵

IS and AS contributed equally as first authors

WV and MG contributed equally as last authors

Correspondence to:

Dr. Erika Graf

Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Stefan-Meier-Str. 26, 79104 Freiburg

Phone: +49/761/203-5000

Mail: egr@imbi.uni-freiburg.de

Key words: Integrated health care, evaluation, indicators, claims data, regional variation

Word count: 4.877

ABSTRACT

Introduction: Patients often experience interface problems when treated by different specialists and in different health care sectors. Integrated care concepts aim to reduce these problems. While most integrated health care models focus on individual diseases, the integrated care model 'Gesundes Kinzigtal' applies a population-based approach and addresses the full spectrum of morbidities for a population defined by area of residence – the Kinzigtal. A special feature of the model is the joint savings contract between the regional management company and the statutory health insurers. The INTEGRAL-study aims at assessing the effectiveness of 'Gesundes Kinzigtal' under routine conditions in comparison to conventional care over a period of 10 years in order to understand the benefits but also the potential for (unintended) harms.

Methods and analysis. Database: Claims data from statutory health insurance funds 2005-2015. The evaluation consists of a quasi-experimental study, with Kinzigtal as intervention region, at least 10 further regions with a similar population and health care infrastructure as primary controls, and an additional random sample of insurees from the federal state of Baden-Wuerttemberg as secondary controls. Model-specific and 'non-specific' indicators, adopted from the literature and enriched by focus group interviews will be used to evaluate the model's effectiveness and potential unintended consequences by analysing health care utilisation in general. Temporal trends per indicator in the intervention region will be compared to those in each control region. The overall variation in trends for the indicators across all regions provides information about the potential to modify an indicator due to local differences in the health care system.

Ethics and dissemination. Ethical approval: Ethic Commission of the Faculty of Medicine, Philipps-University Marburg (ek_mr_geraedts_131117). Results will be discussed in workshops, submitted for publication in peer-review journals, and presented at conferences.

Trial Registration number: German Clinical Trials Register (DRKS00012804).

ARTICLE SUMMARY

A study protocol for a quasi-experimental claims-based study evaluating ten-year results of the population-based integrated health care model 'Gesundes Kinzigtal' (Healthy Kinzigtal): the INTEGRAL study

Strengths and limitations of this study

- Strengths of the present evaluation study include its long observation period and comparisons of the intervention region with regions similar in population and health care infrastructure, which allows to estimate regional variation as well as the effect of the integrated care model.
- The indicators relevant for this assessment will be developed in a structured process independent of the evaluation.
- Another positive feature is the use of 'non-specific indicators' to reveal unintended consequences of the integrated care model and joint savings contract.
- Limitations are those usually associated with collecting claims data, namely, the occurrence of diseases can only be documented and validated internally using the routine data-collecting tools available; patient-reported outcomes (i.e. regarding lifestyle, quality of life, the perception of patient-centered care), data on medical examinations and lab findings are not accessible.
- Moreover, only those services covered by statutory health insurance providers were documented, so that (few) services paid for by the patients themselves were not considered.

INTRODUCTION

Healthcare provision in Germany today is mainly divided into outpatient care (general practitioners (GP) and specialists), hospital care and rehabilitative care. These so-called 'sectoral silos' can be problematic due to their lack of exchange between stakeholders and even lead to poor health outcomes. 'Integrated care' has the potential to address these deficits using new structural approaches beyond the current way of service provision. Close cooperation between GPs, specialists, hospitals and other healthcare stakeholders is intended to lead to more patient-oriented care and cross-sectoral communication. Integrated care aims to improve the quality and cost-effectiveness of healthcare compared to today's situation.¹

The integrated care model 'Gesundes Kinzigtal' (ICM-GK) is considered a best practice example in Germany² and internationally^{3, 4} not least due to its population-oriented approach. Compared to other existing models based on the same contractual approach (so-called selective contracting¹) which focus on integrated care for *selected* diseases, ICM-GK addresses the full spectrum of morbidities and health issues for a population defined by residential area (with the only exception of dental care). The contract was concluded in early 2006 between two partners: the Gesundes Kinzigtal GmbH management company (a joint company founded by the 'Medizinisches Qualitätsnetz Ärzteinitiative Kinzigtal e.V.' (MQNK), a regional physicians' network, and OptiMedis AG, a management and holding company specialized in integrated care) and the AOK Baden-Wuerttemberg (the largest statutory health insurance fund in the federal state of Baden-Wuerttemberg). It is a population-based integrated care contract according to § 140 – SGB V (Book V of the German Social Security Code) as of 01 November 2005. Several months after conclusion, the LKK health insurance ('Landwirtschaftliche Krankenkasse') joined the contract. The contract covers the Kinzigtal region, which is located in the Black Forest in southwest Germany and home of about 70,000 people, about 33,000 of whom are insured with the two statutory health insurers that are contract partners. The insureds, doctors and other providers can choose whether they want to join the contract. Even those insureds who decide to enrol into ICM-GK retain the option to visit doctors and other providers who are not part of the contract. Within ICM-GK, patients are entitled to individual targeted, integrated care which focusses on prevention and quality of life for people with chronic diseases. There are no direct financial incentives for insureds to join the contract. A key goal of the integrated care model is the participation (on different levels) and activation of patients: A patient

¹ In general terms a contract between one mandatory health insurance and a single or a group of providers, as opposed to a "collective contract" between all mandatory health insurances and provider umbrella organisations (usually covering a whole region).

1
2
3 advisory board consisting of several members elected from (and by) the insurees is part of many
4 decision-making processes of the 'Gesundes Kinzigtal' management.⁵ The patient advisory
5 board elects a patient ombudsman who represents patient interests and mediates in case of
6 conflicts.⁶⁻⁸ ICM-GK aims to improve quality and efficiency in health care by dedicated
7 investments in new activities which improve public health or patient care in the long run but
8 simultaneously reduce costs. This is achieved by means of two strategies:

- 13 1) Employing both target group-specific and general prevention and healthcare
14 programmes to reduce incidence and prevalence of morbidities or to delay disease
15 progression.
- 16 2) Managing inter-sectoral interfaces (in particular between outpatient and inpatient care) in
17 order to improve patient management

21 The contract between the management company and the statutory health insurers includes a so-
22 called joint savings contract, i.e. the healthcare cost savings achieved are distributed between
23 the contractual partners ^{2, 6}. Savings are calculated as the difference between the actual
24 healthcare costs and the funds provided to the statutory health insurers to ensure service
25 coverage, which in turn is based on the morbidities prevailing in the region ("morbidity-oriented
26 risk structure compensation scheme"). The calculation of the savings is based on all insurees of
27 both statutory health insurers located in the Kinzigtal, not only those who have enrolled into ICM-
28 GK. Inter alia, this serves to avoid a selection bias in favour of insurees of greater health ⁹. Since
29 a joint savings contract can potentially incentivise lower levels of care, i.e. an under-utilisation of
30 health services ¹⁰⁻¹², an evaluation of the healthcare quality of the model is of high relevance ⁵.

37 The model was built up in several steps between 2006 and 2010. An initial milestone of 8,000
38 insurees of AOK Baden-Wuerttemberg joining was reached in 2011. The start-up phase was
39 accompanied by an evaluation comprising several modules ¹³⁻¹⁸. Another external evaluation
40 study of the model also had its primary focus on the start-up phase¹⁷. Generating knowledge
41 about the effectiveness of an integrated care project under routine conditions (i.e. after the
42 completion of the start-up phase in which the commitment of the stakeholders is extraordinary) is
43 of high relevance for all population-based integrated care programmes and physicians' networks
44 in order to understand the true benefits, but also the potential for (unintentional) harm.

53 **Research aims:**

55 This study protocol describes the evaluation of both the start-up and consolidation phase of the
56 'Gesundes Kinzigtal' model, with special focus on the latter: In order to assess differences to
57

conventional routine care, the integrated care model should be analysed in its routine practice after the completion of the start-up phase, which is now possible for the first time.

The evaluation uses claims data from the statutory health insurer AOK Baden-Wuerttemberg covering the period 2005 to 2015. The evaluation aims to answer the following questions:

- a) Which indicators can be calculated from claims data in Germany in order to measure differences in patients' treatments and outcomes between intervention group and control groups, with regard to ICM-GK prevention and treatment programmes (ICM-GK programme-specific indicators) as well as health care utilisation and health care of the populations under study in general (ICM-GK programme-unrelated non-specific indicators).
- b) Has the quality of healthcare provided on the basis of the joint savings contract remained stable or improved compared to its baseline level in 2005?
- c) How does the development of healthcare quality during the start-up phase (2006-2010) compare to the development during the consolidation phase (2011-2015)?
- d) Does ICM-GK succeed in avoiding under-utilisation of health services although ICM-GK's revenues are based on a joint savings contract?

We expect that the comprehensive set of study indicators based on claims data can also be used for healthcare monitoring in other integrated care models.

METHODS AND DESIGN

Study design:

The evaluation consists of a quasi-experimental study, with the Kinzigtal region as the intervention region and at least 10 other regions with a similar population and health care infrastructure as primary controls and an additional random sample of insurees from the federal state of Baden-Wuerttemberg as secondary controls. Figure 1 depicts the study concept.

Fig 1: Study concept for the evaluation of the integrated care model 'Gesundes Kinzigtal' (ICM-GK)

- *Please insert figure 1 here*

1
2
3
4
5 *IC: integrated care*
6
7
8
9

10 **Work package A: indicator development:**

11
12 A set of quality indicators will be developed to assess the development of quality of care within
13 the study region, and between the study region and the control regions, during the observation
14 period. Based on a mixed methods approach, focus group interviews with stakeholders are
15 combined with a systematic literature review and consensus decision-making.
16
17

18
19 We will develop ICM-GK programme-specific quality indicators to assess ICM-GK goal
20 attainment, and ICM-GK programme-unrelated, non-specific quality indicators to capture
21 potentially unintended consequences of the integrated care model. The indicator development
22 uses, among others, Kessner's tracer concept ¹⁹, the OECD-HCQI criteria ²⁰ to assess the
23 performance of the health system, and as amended by Fung et al. (2008) ²¹, criteria for public
24 reporting initiatives: Thus, above all, indicators should capture effectiveness, safety, patient
25 orientation, and unintended consequences of health care interventions.
26
27
28
29

30
31 Analysing all ICM-GK programs executed during the observation period will be the starting point
32 for the development process. We will then conduct focus group interviews (cf. below, Module
33 A1) and a systematic review of published specific and non-specific indicators (Module A2-A3).
34 Finally, we will decide on the set of indicators for evaluation through consensus decision-making
35 (Module A4).
36
37
38

39
40 Module A1: focus group interviews: In order to shed light on stakeholders' views on ideal
41 concepts of integrated care and potentially unintended consequences, we will perform semi-
42 structured guided interviews. Six stakeholder groups with 4-6 participants each will be
43 interviewed, consisting of patients from the study region (1) / non-study region patients (2),
44 health care providers from the study region who are (3) / are not (4) members of the ICM-GK
45 provider network / non-study region providers (5), and programme managers and participating
46 sickness funds (6). The interviews will be recorded and transcribed. Potential indicators will be
47 extracted.
48
49
50
51

52
53 Module A2: Development of ICM-GK programme-specific indicators: First, we will analyse
54 programme goals and recommended treatment processes of all ICM-GK programmes carried
55 out during the observation period. Second, appropriate indicators to evaluate these programmes
56
57
58
59

1
2
3 will be developed using a) clinical practice guidelines focusing on the diseases addressed by the
4 ICM-GK programmes; b) quality indicator databases (e.g. National Quality Measures
5 Clearinghouse²², The Ambulatory Care Quality Alliance²³, RAND²⁴, National Quality Forum
6 Quality and Outcomes Framework²⁵, District Health Board New Zealand²⁶, OECD Healthcare
7 Quality Indicators²⁷, and the German databases AQUIK²⁸, QUINTH²⁹, and QISA³⁰); c) a review of
8 articles published in PubMed, Cochrane Library, Embase, Web of Science containing the search
9 terms 'quality indicator*' and 'integrated care'; d) programme-specific indicators mentioned in the
10 focus group interviews. Two independent reviewers will screen abstracts and full texts of articles,
11 guidelines and QI databases for indicators suitable to measure the quality of programme-specific
12 processes and outcomes of care. We will search the mentioned databases for English and
13 German articles without time limit. Our focus will be on indicators assessing integrated care,
14 health promotion and prevention. We will exclude indicators focusing on practice management
15 and in-hospital care. All potential indicators will be extracted and entered into a database using
16 the scheme developed by the Joint Commission on Accreditation of Healthcare Organizations
17 (1990)³¹ to describe the indicators. We will eliminate duplicates and check whether the
18 respective indicator could be calculated using routine claims data of German sickness funds.
19 The final list of suitable indicators will be assessed by the consensus panel (see A4).
20
21
22
23
24
25
26
27
28
29

30
31 Module A3: Development of ICM-GK programme-unrelated non-specific indicators: Indicators for
32 the assessment of health care utilisation and the health status of the regional intervention and
33 control populations will serve to identify potential under- or overuse of services that are not in the
34 focus of ICM-GK programmes in the Kinzigtal region. Therefore, we will use OECD indicators
35 (<https://data.oecd.org/health.htm>), the frequency of ICD groups, prescription drug categories
36 (ATC groups), and outpatient or inpatient procedures conducted in the intervention and control
37 regions. We will differentiate between age groups, gender and people with/without
38 multimorbidity.
39
40
41
42
43

44 Module A4: Consensus decision-making: A panel of 10 participants will be invited to finally
45 assess the validity and feasibility of the indicators. As participants we will choose two healthcare
46 providers of the ICM-GK network, two patient representatives of ICM-GK, one sickness fund
47 representative, three members of the evaluation team who were not involved in indicator
48 development and two quality indicator experts. We will use a modified RAND/UCLA
49 Appropriateness Method (RAM)²⁸ and provide participants with information on the indicator
50 development methodology and the consensus process at a first meeting. Participants will
51 receive an online or print version of the indicator set to rate the validity and feasibility of the
52 indicators on a 9-point Likert scale. In a subsequent face-to-face meeting, the participants will be
53
54
55
56
57
58
59
60

1
2
3 invited to discuss the summary ratings of indicators and comments upon which participants did
4 not agree. Participants will then rate the remaining indicators a second time. Appropriate
5 indicators without disagreement will constitute the final indicator set.
6
7

8 The indicators pre-specified in work package A will be later supplemented by a data-driven
9 statistical search considering a wide range of non-prespecified indicators based on diagnoses,
10 prescriptions and procedures.
11
12
13

14 15 16 **Work package B: Claims data analysis of indicators for evaluation:**

17 18 Database and observation period:

19
20 The evaluation is based on retrospective claims data of the major health insurer involved, the
21 AOK Baden-Wuerttemberg. Anonymised data will be provided by the AOK Research Institute
22 (Wissenschaftliches Institut der AOK - WiDO). In addition to master data (with information e.g.
23 concerning age, gender, insurance status and period of insurance), information on the use of all
24 sectors of health care (outpatient care, hospital care, drug prescriptions, benefits in kind, long-
25 term care) is available and can be linked using a non-identifiable study number. For the analysis,
26 ICD-10 coded diagnoses – available since the year 2000 - from out- and inpatient care are
27 provided, further medical services according to the EBM Code (physician fee schedule), drug
28 prescription with pharmaceutical registration number and linkage to Anatomical Therapeutic
29 Chemical (ATC) classification and Defined Daily Dose (DDD), hospital stays with e.g. ICD-10
30 coded diagnoses, procedures ('OPS' Codes) and length of stay, benefits in kinds, information
31 concerning inability to work (diagnosis, duration) and utilisation of long-term care.
32
33
34
35
36
37
38
39

40 Data are provided for the years 2005 to 2015 with 2005 as reference year, i.e. the year before
41 the start of the integrated care programme. The ICM GK project defined a number of 8.000
42 enrolled patients as a precondition to open the program for other sickness funds. This number
43 was reached in 2011, therefore we will take the years 2006 to 2010 as the start-up phase, 2011
44 to 2015 as the consolidation phase. Furthermore, the increase of enrollments has remarkably
45 slowed down from 2011, showing that enrolment dynamics is another feature suggesting that we
46 may differentiate those two development phases.
47
48
49
50
51
52
53

54 Target population and control populations:

55
56
57
58
59
60

1
2
3 The target population consists of all AOK insurees living in the intervention region irrespective of
4 any enrollment – this results from the conception of the ICM-GK as a regional population-based
5 health care system covering virtually all health care sectors and health conditions. AOK insurees
6 are assigned to the intervention population („Kinzigal population“) if the postal code of their
7 place of residence encodes a place within the Kinzigal region (German postal codes 77709-
8 77797 and 78132). The target population consists of about 30.000 AOK insurees in 2005 and of
9 nearly 32.000 insurees in 2015, and they will be surveyed completely.
10
11
12
13

14 Control populations (from regions characterised by ‘conventional’ or ‚usual care‘) are necessary
15 to check whether the developments observed in the intervention region are actually specific for
16 the latter and may thus be attributed to ICM-GK activities or whether they correspond to a
17 general trend or a small-scale variation pattern which may also occur under other
18 circumstances. For this purpose, we will analyse two types of control populations: First we will
19 consider all AOK insurees from at least 10 control regions (identified by distinct postal codes);
20 these regions shall be structurally similar to the Kinzigal region. A structurally similar control
21 region should meet the following requirements: It should be a geographically contiguous area i)
22 containing only rural communities, small towns or – at most – small medium-sized towns with
23 less than 50.000 inhabitants each; ii) it should preferably be characterised by a river valley,
24 comparable to the Kinzigal region; iii) important socio-economic and health service indicators of
25 a control region should not deviate too much from its counterpart in the Kinzigal region. As
26 important socio-economic and health service indicators we will consider 1) unemployment rate in
27 2005-2007, 2) income tax per inhabitant in 2005-2007, 3) commuter flow in 2014, 4) proportion
28 of foreign residents in 2015, 5) proportion of employees with academic education in 2015, 6)
29 proportion of employees without training qualifications in 2015, 7) average distance to the
30 closest hospital (in minutes by car), 8) number of inhabitants per office-based general
31 practitioner in 2015, and 9) number of inhabitants per office-based physician or psychotherapist
32 in 2015. Additionally, we will check whether there is an active network of physicians in a given
33 region – a network comparable to the one which was active in the intervention region at the time
34 when the integrated health care system was launched. (We assume that such a network might
35 contribute to an above-average quality of health care.) Our goal is to select 50% of control
36 regions with such a network and 50% without. Apart from this control population, we will draw a
37 random sample of about 500,000 AOK insurees residing in the German federal state of Baden-
38 Wuerttemberg, but outside of the Kinzigal region. The comparison with the first type of control
39 groups will be our primary comparison, the one with the random sample a secondary
40 comparison.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Before operationalising and analysing the study populations, we will investigate how many AOK
4 insurees have not been insured continuously throughout a given year or whether insurees were
5 not resident in the region concerned all year round. Depending on this investigation's results, we
6 will settle the final criteria for the inclusion in the study population.
7
8

9
10 Health services for AOK insurees in the federal state of Baden-Wuerttemberg outside of the
11 Kinzigtal region are currently largely characterized by family doctor-centred health care – an
12 AOK programme which also aims at a higher quality of health care and requires insurees to
13 enroll, thereby choosing their family doctor. Unfortunately, for some health services this implies a
14 lack of data regarding these patients, as they are covered by a general fee for the GP.
15 Therefore, we have to exclude these patients from the analysis of some indicators.
16
17
18

19 20 Operationalization of indicators for data analysis

21
22 In a first step, we operationalise the indicators consented in work package A for the routine data
23 analysis. For indicators expressed as a percentage of a target population, the nominator and
24 denominator have to be defined with the information available in claims data. For each target
25 population, the inclusion and exclusion criteria have to be determined (e.g. ICD-10 codes,
26 validation criteria, insurance period). Indicators will address processes of care as well as
27 outcomes. For the process-related indicators, e.g. billing codes for outpatient care services
28 (EBM codes) and inpatient services (OPS codes) will be used for assessment. Outcomes are
29 mostly clinical events which can be mapped with diagnoses. Other outcomes refer to the
30 utilisation of special services such as long-term care, palliative care or rehabilitation. All-cause
31 mortality will be assessed using variable 'death' as the reason for leaving the sickness fund.
32
33
34
35
36
37
38
39
40

41 Statistical considerations:

42
43 In the descriptive part of the study, we present the percentage of the insured persons or the
44 specific target population fulfilling the respective indicator. For the inferential part, our basic
45 approach is to determine for each indicator and each region the temporal trend in the indicator
46 and to compare the trend observed in the intervention region 'Kinzigtal' with the trends in the
47 control regions. The overall variation in trends across all regions provides information about the
48 potential to modify an indicator due to local differences in the health care system. If there is
49 some variation and if the trend in the intervention region is smaller (or larger) than in all or in the
50 vast majority of control regions, we will regard this as an indication of a specific situation in the
51 intervention region, which is likely to be causally related to the ICM-GK.
52
53
54
55
56
57
58
59
60

1
2
3
4
5 The estimation of the temporal trends will be based on combining regression models for the
6 individual patient data with a standardisation for the population of Baden-Wuerttemberg based
7 on the full random sample from the latter. The choice of the regression models will depend on
8 the type of indicator: For binary indicators, we use logistic regression models, for other types, we
9 select the model accordingly.
10
11

12 In our analytic approach, the following issues will be taken into account:
13

- 14 • *Changes in population over time:* The populations in the regions will change over time due to
15 migration, fertility and mortality. We aim at including at each time point all patients living in
16 the respective region in order to avoid any selection effects. The fact that the same patients
17 will contribute to the same indicator at different time points will be taken into account when
18 assessing statistical significance.
19
- 20 • *Baseline differences across regions:* We avoid any assumptions about similarity across
21 regions at baseline by using regions as fixed effects in all analyses. In spite of the structural
22 similarity of all regions we have to expect differences in the distribution of age, gender,
23 comorbidity, and social status. Consequently, we will adjust all analyses for the first three
24 factors at the individual level and for the fourth factor at the postal code level.
25
- 26 • *Global time trends and structural changes:* Due to using several control regions as well as a
27 sample from the whole BW population, we are able to detect global time trends as well as
28 global structural changes over time, e.g. due to administrative changes in the health care
29 system. We can account for this by using the calendar year as a categorical covariate in all
30 analyses, and hence require the linearity of region specific trends only in addition to a
31 potentially non-linear global trend.
32
- 33 • *Time window for trends and stability of trends:* For each indicator, we will a priori define a
34 starting point at which we expect a specific change in the time trend (e.g. due to the start of a
35 specific programme) as well as the period over which we expect the change to continue. If
36 the starting point lies within the first 3 years of our observation period, we will also analyse
37 the stability of the trend over time, in particular whether we can find evidence for an
38 attenuation of the trend.
39
- 40 • *Assessing a specific role of the intervention region:* In order to assess a potential specific
41 role of the intervention region, we will visualize trend estimates of all regions in a forest plot
42 as well as in a dot plot. A formal assessment will be based on assessing the statistical
43 significance of a deviation of the intervention region from the mean of all control regions and
44 from the Baden-Wuerttemberg region and on the representation of the deviation of the
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 intervention region from the mean of the control regions as a z-score, i.e. in the unit of the
4 standard deviation of the variation across the control regions.

- 5
6 • *Floor and ceiling effects*: Some regions may for some indicators be already close to the
7 maximum or minimum we can expect. Such circumstances can distort the interpretation of
8 trends. We will take this into account by performing additional analyses which will give more
9 weight to the control regions which are initially similar to the intervention region.
- 10
11 • *Provider effects*: Indicators reflecting an action by a health care provider may be prone to
12 provider effects, i.e. the main source of variation may be differences between providers. We
13 will take this into account when assessing statistical significance whenever the action can be
14 assigned to a health care provider (typically the GP) in our data. In addition, provider
15 variation within regions and their temporal trends will be described and the intervention
16 region will be compared with the control regions.
- 17
18 • *Reducing trends to a single number*: Such a reduction is necessary in order to allow the
19 necessary comparisons between regions. However, this may fail to take a more complex
20 development into account. We will address this issue by always additionally visualizing the
21 raw data behind each estimated trend.
- 22
23 • *Multiplicity*: By comparing the trend estimate in the intervention region simultaneously with all
24 trends in the control regions, we avoid multiple testing when analysing a single indicator. It
25 remains to be borne in mind that we analyse a large number of indicators for a possible
26 specific role of the intervention region. We approach this by assessing global measures such
27 as the number of indicators hinting towards such a specific role or the average difference
28 from the control regions. We will do this in a hierarchical manner, taking into account pre-
29 specified groupings of the indicators, reflecting the suspicion that some indicators might
30 reflect the same signal.
- 31
32 • *Ranking of non-pre-specified indicators*: A huge number of non-pre-specified indicators will
33 be investigated with the aim to identify the most relevant potential signals. Here we will make
34 use of statistical methods, which have been successfully applied in analysing signals for
35 unknown side-effects of drugs based on routine data.³²

36
37
38
39
40
41
42
43
44
45
46
47
48
49 Details of the analytical approach will be fixed in a statistical analysis plan to be finalized prior to
50 starting the analyses.

51
52
53
54 Data will be stored on MS-SQL Server 2014 under Windows Server 2012. The analysis will be
55 performed with SQL, SAS for Windows Release 9.3 (SAS Institute Inc. Cary, N.C. USA) and
56
57

1
2
3 Stata 15.1. (StataCorp. 2017. Stata Statistical Software: Release 14. College Station, TX:
4 StataCorp LP). The use of claims data follows the Guideline for Good Practice of secondary data
5 analysis³³. Essential parts are contracts with data owner and the regulations for data privacy.
6
7

8 **PATIENT AND PUBLIC INVOLVEMENT**

9

10 Patients and public were not involved in the study design nor will they be involved in the
11 recruitment and conduct of the study. Patient will be involved in focus groups addressing
12 aspects of integrated care and in the consensus panel assessing validity and feasibility of the
13 indicators for evaluation.
14
15

16 **ETHICS AND DISSEMINATION**

17

18 Ethical approval has been obtained from the Ethic Commission of the Faculty of Medicine,
19 Philipps University Marburg (ek_mr_geraedts_131117). All participants in the focus groups (work
20 package A, cf. figure 1) will give their informed consent, which can be withdrawn at any time
21 during the study. The analysis of the meetings and the presentation of the results (work package
22 C; cf. figure 1) will be is anonymous. Participants will not be identified in any publication.
23
24
25

26 Access to the claims data is regulated by a contract between the AOK Research Institute (WIdO)
27 and the researchers who analyse the data. Claims data for the evaluation analysis are provided
28 in an anonymised manner, therefore no informed consent is necessary. The internal project
29 study number does not allow any re-identification of the insurees.
30
31
32

33 After completion of the project, a workshop with relevant stakeholders and participants of the
34 focus groups is planned in order to discuss the results (work package C, cf. figure 1) and to start
35 a process for disseminating results and transferring the methodology used to evaluate an
36 integrated care model. A study report with an executive summary will be produced and will be
37 made available for those contributing to the study and other interested parties.
38
39
40

41 Besides, results of the study will be presented at scientific conferences and submitted for
42 publication in peer-reviewed journals. The indicators and transfer to routine data analysis will be
43 provided (e.g. via an electronic platform) for those interested in the evaluation of the service
44 quality of population-based integrated care.
45
46
47

48 **DISCUSSION**

49

50 A solid and thorough assessment of integrated care models is essential to evidence-based
51 health care. A particular feature of this project is the long observation period, which is made
52 possible by using routine data from the statutory health insurance funds. Although investigating
53
54
55
56
57

1
2
3 the effects of complex interventions by relying on routine data entails certain limitations, it
4 remains a reasonable and acceptable procedure. For example, the Pay-for-
5 Performance (P4P) programme ^{34, 35}, Preferred Provider Organisation Settings ³⁶, and Patient-
6 centered Medical Home ^{37, 38} were assessed with administrative data. In Germany, data from
7 health insurance funds were used to evaluate disease management programmes (DMP) ^{39 40}
8 and family doctor-centered care (Hausarztzentrierte Versorgung) ⁴¹⁻⁴⁴ as well as models of
9 integrated care ^{45, 46}, not least because of their advantages such as availability for long periods
10 of time without additional data collection, no selection, interviewer or recall bias – thus reflecting
11 everyday practice of health care.
12
13
14
15

16
17 Our study aims to show whether the ICM-GK's standard of care is at least equivalent, better or
18 worse than that of 'conventional' or 'usual care' during the consolidation phase of ICM-GK. This
19 project reveals evidence for the design of the population-based integrated care contract not only
20 for the ICM-GK, but also for health insurers and other stakeholders of health care structures in
21 Germany. Should this evaluation reveal weaknesses in certain areas (such as under-use or
22 inadequate care), similarly-structured types of care involving selective contracts could make it
23 possible to take countermeasures (i.e. committing to continuous and prompt monitoring of care
24 by employing specific codes or the obligatory publication of results as well as the redrafting of
25 certain contractual regulations such as joint savings contracts).
26
27
28
29
30

31 The indicators developed here can also be employed to control quality and managed health care
32 in other types of integrated care, and for monitoring the provision of standard care. The
33 development process of the indicators, involving relevant stakeholders, ensures their relevance
34 for the practice and for health care provision itself.
35
36
37
38
39

40 **Author affiliations**

41
42 ¹PMV research group at the Department of Child and Adolescent Psychiatry, Psychotherapy and
43 Psychosomatic, University of Cologne, Herderstraße 52, 50931 Cologne, Germany

44
45
46 ²Institute of Occupational and Social Medicine and Health Services Research – University
47 Hospital Tübingen; Wilhelmstr. 27, 72074 Tübingen, Germany

48
49
50 ³ Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center -
51 University of Freiburg, Stefan-Meier-Str. 26, 79104 Freiburg, Germany
52
53
54
55
56
57
58
59
60

⁴Institute of Medical Biometry and Statistics, Section of Health Care Research and Rehabilitation Research, Faculty of Medicine and Medical Center - University of Freiburg, Hugstetter Str. 49, 79106 Freiburg, Germany

⁵Institute for Health Services Research and Clinical Epidemiology, University Marburg; Karl-von-Frisch-Straße 4, 35043 Marburg, Germany

⁶ AOK Research Institute (WIdO), Berlin; Rosenthaler Straße 31, 10178 Berlin, Germany

⁷ Department of Orthopaedics and Traumatology, University Hospital Basel, Spitalstr. 21, 4031 Basel, Switzerland

Ethical approval: The study has been granted ethical approval by Ethic Commission of the Faculty of Medicine, Philipps-University Marburg (ek_mr_geraedts_131117).

AUTHOR CONTRIBUTIONS

MG, EFG, EG, IS, AS and WV are principle investigators and responsible for the study design and project management. CG, PD, AK, IK and PI are responsible for data provision, data collection, and data management. IK, PI, DS, WV and EG are responsible for the statistical analysis, AS and WV for the concept of defining control regions. MG, JS and CM are responsible for the indicator development, IK and IS for the operationalisation of indicators with routine data. All authors reviewed and approved the final version of the study protocol.

Provenance and peer review. Externally peer reviewed

Funding statement

The project is funded by the Innovation Committee of the Joint Federal Committee after peer review by the scientific advisory board under the grant number 01VSF16002.

Competing interests: AS declares involvement in former studies on Gesundes Kinzigtal GmbH (2006-2015) and an employment at Gesundes Kinzigtal GmbH (01-June-2015 until 31-December-2015). IS, IK and PI declare that they were involved in one former study evaluating the start-up phase (2006-2011) of the integrated care model 'Gesundes Kinzigtal'. All authors report grants from the Innovation Committee of the Joint Federal Committee, during the conduct of the study.

Patient consent: not required

Acknowledgements: The authors would like to thank the AOK Baden-Wuerttemberg for data access and Susanne Sollmann (WIdO) for her help with translating the protocol. The article

1
2
3 processing charge was funded by the German Research Foundation (DFG) and the University of
4 Freiburg in the funding programme Open Access Publishing.
5

6
7 **Data statement:** Technical appendix, details on statistics, and data tabulations will be made
8 available from <http://www.pmvforschungsgruppe.de>.
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. Groene O, Pimperl A, Hildebrandt H. The Role of Integrated Care and Population Health. Cham Palgrave Macmillan, 2017.
2. Sachverständigenrat zur Begutachtung der Entwicklung im Gesundheitswesen. Koordination und Integration. Gesundheitsversorgung in einer Gesellschaft des längeren Lebens. Sondergutachten 2009. Langfassung, 2009.
3. Pimperl A, Hildebrandt H, Gröne O, et al. Case Study: Gesundes Kinzigtal Germany. In: McClellan M, ed. *Accountable Care in Practice: Global Perspectives*. Durham: Duke-Margolis Center for Health Policy, 2017.
4. Groene O, Pfaff H, Hildebrandt H. Germany: Scaling Up a Population-Based Integrated Healthcare System: The Case of "Healthy Kinzigtal" in Germany. In: Jeffrey Braithwaite RM, Yukihiro Matsuyama, Paul Shekelle, Stuart Whittaker and Samir Al-Adawi, ed. *Health Systems Improvement Across the Globe: Success Stories from 60 Countries*. Boca Raton, London, New York: CRC Press 2018.
5. Siegel A, Stossel U, Schubert I, et al. [Problems of evaluating regional integrated care using the example of "Gesundes Kinzigtal Integrated Care"]. *Z Evid Fortbild Qual Gesundheitswes* 2011;105(8):590-96.
6. Herrmann C, Hildebrand H, Richter-Reichhelm M, et al. Das Modell „Gesundes Kinzigtal“ – Managementgesellschaft organisiert Integrierte Versorgung einer definierten Population auf Basis eines Einsparcontractings. *Gesundheits Sozialpolitik* 2006;5(6):11-29.
7. Hildebrandt H, Herrmann C, Knittel R, et al. Gesundes Kinzigtal Integrated Care: improving population health by a shared health gain approach and a shared savings contract. *International Journal of Integrated Care* 2010;10
8. Pimperl A, Schreyögg J, Rothgang H, et al. Ökonomische Erfolgsmessung von integrierten Versorgungsnetzen—Gütekriterien, Herausforderungen, Best-Practice-Modell. *Das Gesundheitswesen* 2015;77(12):e184-e93.
9. Siegel A, Köster I, Schubert I, et al. Utilization dynamics of an integrated care system in Germany: Morbidity, age, and sex distribution of Gesundes Kinzigtal integrated care's membership in 2006–2008. In: Janssen C, Swart E, Lengerke T, eds. *Health care utilization in Germany Theory, Methodology, and Results* Foreword by Ronald M Anderson. New York: Springer 2014:321-35.
10. Porter ME, Teisberg EO. *Redefining health care: creating value-based competition on results*: Harvard Business Press 2006.
11. Berchtold P, Hess K. Evidenz für managed care: europäische Literaturanalyse unter besonderer Berücksichtigung der Schweiz: Wirkung von Versorgungssteuerung auf Qualität und Kosteneffektivität. Neuchatel: Schweizerisches Gesundheitsobservatorium 2006.
12. Jacobs K, Schulze S. Managed Care und integrierte Versorgung in den USA—Erfahrungen und Lehren für die Diskussion in Deutschland. In: Klauber J, Robra BP, Schellschmidt H, eds. *Krankenhaus-Report: Wege zur Integration*. Stuttgart: Schattauer-Verlag 2005:81-97.
13. Hölzel L, Vollmer M, Kriston L, et al. Patientenbeteiligung bei medizinischen Entscheidungen in der Integrierten Versorgung Gesundes Kinzigtal: Ergebnisse einer kontrollierten Kohortenstudie. *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 2012;55(11-12):1524-33.
14. Mnich E, Hofreuter-Gätgens K, Salomon T, et al. Ergebnis-Evaluation einer Gesundheitsförderungsmaßnahme für ältere Menschen. *Gesundheitswesen* 2013;75(02):e5-e10. doi: 10.1055/s-0032-1311617 [published Online First: 21.05.2012]
15. Siegel A, Stöbel U. Prozessevaluation aus Sicht der Leistungserbringer: Ergebnisse der Erst-, Zweit- und Drittbefragung der Leistungspartner (PeGL-Projekt), Teil III. EKIV Newsletter Freiburg: Evaluations-Koordinierungsstelle Integrierte Versorgung Gesundes Kinzigtal, 2012:4-7.

16. Hildebrandt H, Pimperl A, Schulte T, et al. Triple Aim – Evaluation in der Integrierten Versorgung
Gesundes Kinzigtal – Gesundheitszustand, Versorgungserleben und Wirtschaftlichkeit. *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 2015;58(4-5):383-92.
17. Schubert I, Siegel A, Köster I, et al. Evaluation der populationsbezogenen ,Integrierten Versorgung
Gesundes Kinzigtal '(IVGK). Ergebnisse zur Versorgungsqualität auf der Basis von Routinedaten. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2016;117:27-37.
18. Siegel A, Stöbel U. Patientenorientierung und Partizipative Entscheidungsfindung in der Integrierten
Versorgung Gesundes Kinzigtal. In: Pundt J, ed. *Patientenorientierung: Wunsch oder Wirklichkeit*.
Bremen: Apollon 2014:195-230.
19. Kessner DM, Kalk CE, Singer J. Assessing Health Quality-the Case for Tracers. *New England Journal of
Medicine* 1973;288(4):189-94. doi: 10.1056/nejm197301252880406
20. Arah OA, Westert GP, Hurst J, et al. A conceptual framework for the OECD Health Care Quality
Indicators Project. *International Journal for Quality in Health Care* 2006;18(suppl_1):5-13. doi:
10.1093/intqhc/mzl024
21. Fung CH, Lim Y-W, Mattke S, et al. Systematic review: the evidence that publishing patient care
performance data improves quality of care. *Annals of internal medicine* 2008;148(2):111-23.
22. AHRQ. National Quality Clearinghouse [Available from: <https://www.qualitymeasures.ahrq.gov/>
accessed 10.07 2018.
23. AHRQ. The Ambulatory Care Quality Alliance: Improving Clinical Quality and Consumer
Decisionmaking [Available from: [https://archive.ahrq.gov/professionals/quality-patient-
safety/quality-resources/tools/ambulatory-care/background.html](https://archive.ahrq.gov/professionals/quality-patient-safety/quality-resources/tools/ambulatory-care/background.html) accessed 10.07. 2018.
24. RAND Corporation. Health Care Quality Indicators 2018 [Available from:
<https://www.rand.org/topics/health-care-quality-indicators.html> accessed 10.07. 2018.
25. National Health Service. Quality and Outcomes Framework 2018 [Available from:
[https://www.nhsbsa.nhs.uk/prescription-data/prescribing-data/quality-and-outcomes-
framework-qof](https://www.nhsbsa.nhs.uk/prescription-data/prescribing-data/quality-and-outcomes-framework-qof) accessed 10.07.2018.
26. District Health Board New Zealand. 2018 [Available from: [https://www.health.govt.nz/new-zealand-
health-system/key-health-sector-organisations-and-people/district-health-boards](https://www.health.govt.nz/new-zealand-health-system/key-health-sector-organisations-and-people/district-health-boards) accessed
10.07.2018.
27. OECD Healthcare Quality Indicators. 2018 [Available from: [http://www.oecd.org/els/health-
systems/health-care-quality-indicators.htm](http://www.oecd.org/els/health-systems/health-care-quality-indicators.htm) accessed 10.07.2018.
28. Kleudgen S, Diel F, Burgdorf F, et al. KBV entwickelt Starter-Set ambulanter Qualitätsindikatoren–
AQUIK®-Set. *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen*
2011;105(1):54-63.
29. QUINTH. Qualitätsindikatorenthesaurus: GKV Spitzenverband; 2018 [Available from:
<https://quinth.gkv-spitzenverband.de/content/index.php> accessed 10.07. 2018.
30. QiSA. Das Indikatorensystem für die ambulante Versorgung: AOK Gesundheitskasse; 2018 [Available
from: <http://www.aok-gesundheitspartner.de/bund/qisa/index.html> accessed 10.07. 2018.
31. Joint Commission on Accreditation of Healthcare Organizations (JCAHO). Primer on indicator
development and application: measuring quality in health care. Oakbrook Terrace, Ill: JCAHO
1990.
32. Efron B. Size, Power and False Discovery Rates. *The Annals of Statistics* 2007;35(4):1351-77.
33. Swart E, Ihle P, Gothe H. Gute Praxis Sekundärdatenanalyse (GPS). Die 2. Revision. *Das
Gesundheitswesen* 2012;74(08/09):A123.
34. Levin-Scherz J, DeVita N, Timbie J. Impact of pay-for-performance contracts and network registry on
diabetes and asthma HEDIS® measures in an integrated delivery network. *Medical Care Research
and Review* 2006;63(1_suppl):14S-28S.

- 1
2
3 35. Fagan PJ, Schuster AB, Boyd C, et al. Chronic Care Improvement in Primary Care: Evaluation of an
4 Integrated Pay-for-Performance and Practice-Based Care Coordination Program among Elderly
5 Patients with Diabetes. *Health Services Research* 2010;45(6p1):1763-82.
6
7 36. Gilmore AS, Zhao Y, Kang N, et al. Patient outcomes and evidence-based medicine in a preferred
8 provider organization setting: a six-year evaluation of a physician pay-for-performance program.
9 *Health Services Research* 2007;42(6p1):2140-59.
10
11 37. DeVries A, Li C, Sridhar G, et al. Impact of medical homes on quality, healthcare utilization, and costs.
12 *The American Journal of Managed Care* 2012;18(9):534-44.
13
14 38. Rosenthal MB, Friedberg MW, Singer SJ, et al. Effect of a multipayer patient-centered medical home
15 on health care utilization and quality: the Rhode Island chronic care sustainability initiative pilot
16 program. *JAMA Internal Medicine* 2013;173(20):1907-13.
17
18 39. Miksch A, Laux G, Ose D, et al. Is there a survival benefit within a German primary care-based disease
19 management program? *The American journal of managed care* 2010;16(1):49-54.
20
21 40. Linder R, Ahrens S, Köppel D, et al. Nutzen und Effizienz des Disease-Management-Programms
22 Diabetes mellitus Typ 2. *Deutsches Ärzteblatt* 2011;108(10):155-62.
23
24 41. Roehl I, Beyer M, Gondan M, et al. Leitliniengerechte Behandlung bei chronischer Herzinsuffizienz im
25 Rahmen der Hausarztzentrierten Versorgung. Ergebnisse einer Evaluationsstudie. *Zeitschrift für*
26 *Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2013;107(6):394-402.
27
28 42. Laux G, Szecsenyi J, Mergenthal K, et al. Hausarztzentrierte Versorgung in Baden-Württemberg.
29 *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 2015;58(4-5):398-407.
30
31 43. Gerlach F, Szecsenyi J. Evaluation der Hausarztzentrierten Versorgung (HzV) nach § 73b SGB V in
32 Baden-Württemberg (2013–2016). *Ergebnisbericht (Stand 0909 2014) Frankfurt und Heidelberg*
33 *Verfügbar unter www.aok-bw-presse.de/src/php/download.php 2014*
34
35 44. Karimova K, Uhlmann L, Hammer M, et al. The development of diabetes complications in GP-
36 centered healthcare. *Am J Manag Care* 2018;24(7):322-27. [published Online First: 2018/07/19]
37
38 45. Braun G, Gröbner M, Seitz R. Evaluation vernetzter Versorgungsstrukturen: Ergebnisse einer
39 empirischen Untersuchung. *Gesundheitsökonomie & Qualitätsmanagement* 2008;13(06):358-64.
40
41 46. Kerkemeyer L, Mostardt S, Biermann J, et al. Evaluation of an integrated care program for
42 schizophrenia: concept and study design. *European archives of psychiatry and clinical*
43 *neuroscience* 2015;265(2):155-62. doi: 10.1007/s00406-014-0508-6 [published Online First:
44 2014/06/08]
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60